

**Carboxy Terminus**

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

## CHEMOTACTIC, ANTIBIOTIC AND LIPOPOLYSACCHARIDE-BINDING PEPTIDE FRAGMENTS OF CAP37

### FIELD OF THE INVENTION

5       The present invention relates to methods of making and using novel peptide fragments derived from CAP37, which is an approximately 37,000 dalton cationic granule protein normally synthesized by human polymorphonuclear leukocytes. In particular, this invention relates to novel peptides having monocyte chemotactic activity, such as peptides having the amino acid sequences  
10 shown in the Sequence Listing as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6 and novel peptides having antibiotic activity or lipopolysaccharide-binding activity, such as peptides having the amino acid sequences shown in the Sequence Listing as SEQ ID NO:7 and SEQ ID NO:8.

15       Throughout this application, various publications are referenced. Full citations for these publications may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

20

### BACKGROUND OF THE INVENTION

In the process of inflammation an initial wave of inflammatory cells, comprised primarily of polymorphonuclear leukocytes (PMN) is soon followed by a second wave of cells, which are predominantly monocytes (Hurley et al.;  
25 Wilkinson et al.). Although it is widely held that monocytes arrive at an area of inflammation as a result of chemotaxis (Hayashi et al.), the specific mediator(s) responsible for the recruitment of monocytes has remained unresolved.

Monocytes are derived from pro-monocytes, found in bone marrow. The pro-monocytes differentiate into monocytes which are released into the blood.  
30 The monocytes circulate in the blood until they are attracted to the site of injury by the inflammation process. Once monocytes enter into tissue they mature into macrophages, also referred to as mononuclear phagocytes. Macrophages are able to engulf and destroy foreign antigens; accordingly, macrophages play an

important role in the body's immunological defense system. The term "monocyte" as used herein refers collectively to both circulating monocytes and to macrophages present in tissue.

The preferential migration of monocytes during the latter phase of inflammation indicates the requirement for highly cell-specific chemoattractant, which has little or no effect on the migration of PMNs. Experiments indicate that a granule-associated cationic protein (mol. wt. 37,000 daltons) from human PMN acts as a monocyte-specific chemoattractant. This protein has been previously referred to in the literature as CAP37, cationic antimicrobial protein of mol. wt. 37,000 daltons. CAP37 protein has been previously shown to (i) bind bacterial lipopolysaccharides with a high degree of specificity and affinity, and (ii) possess antimicrobial activity against a number of Gram negative bacteria, such as *Salmonella typhimurium* and *Escherichia coli* (Shafer et al., 1986). Thus, CAP37 may play three important functional roles in host defense.

While use of purified CAP37 has far reaching and important functions involving the cellular progression of inflammation, antimicrobial and antineoplastic defenses of the host, the activity of CAP37 as isolated from human PMNs may be limited because of (1) the very small quantities that can be purified and (2) the potential hazards of using human blood products. Use of recombinant CAP37 may overcome some of these problems, but CAP37 is still a large molecule (approx. 24,000 daltons). However, synthetic peptide fragments derived from CAP37 that possess chemotactic, antimicrobial or LPS binding activity and are considerably smaller (e.g., about 25 amino acids in length; approx. 2500-3000 daltons) would overcome these problems. That is, these fragments would be conveniently sized, capable of being produced in unlimited quantities and possess a non-infectious nature.

The instant specification discloses a conventional method for purifying CAP37 to homogeneity and a method for making CAP37 using recombinant DNA techniques. The characterization of the cDNA encoding human CAP37 protein is disclosed. The instant specification has also advanced the art into uncharted areas by disclosing proteins and peptides related and/or derived from CAP37 that have monocyte chemotactic activity, antibiotic activity or

lipopolysaccharide (LPS) binding activity. These proteins and peptides can either be synthesized or produced using recombinant DNA techniques. Finally, the instant specification discloses methods for treating diseases and wounds using CAP37 and its related proteins and peptides as well as antibodies to

5 CAP37 and proteins and peptides derived from CAP37 and methods of using these antibodies.

### SUMMARY OF THE INVENTION

An object of the present invention is to provide a recombinant DNA

10 molecule encoding a cationic granule protein having the amino acid sequence shown in the Sequence Listing as SEQ ID NO:9. This protein is a potent chemoattractant for monocytes, is bactericidal and is capable of binding bacterial lipopolysaccharide.

The invention further includes DNA molecules encoding amino terminal

15 extensions of the cationic granule protein such as, (a) the amino acid sequence shown in the Sequence Listing as SEQ ID NO:10 (Met Thr Arg Leu Thr Val Leu Ala Leu Leu Ala Gly Leu Leu Ala Ser Ser Arg Ala Gly Ser Ser Pro Leu Leu Asp), and (b) Met. The invention also includes DNA molecules encoding carboxy terminal extensions such as Gly Pro Ala.

20 Another important object of the present invention is to provide a recombinant method of producing the cationic granule proteins encoded by the above described sequences. These proteins include the above described amino terminal extensions as well as other modifications, such as the attachment, to the amino or the carboxy terminus of the sequence, of a second protein coding

25 sequence. One example of such a second protein coding sequence is the ricin A chain. Other examples include abrin A chain and trichosanthin. One method of recombinant production is the expression of the cationic granule protein coding sequence fused to the glutathione-S-transferase protein (Sj26) with an in-frame thrombin cleavage site separating the two coding sequences. The fusion protein

30 is then isolated by affinity chromatography for the Sj26 protein portion of the fusion protein, and the cationic granule protein is liberated from the fusion protein by digestion of the fusion protein with the thrombin proteinase.

It is an object of this invention to identify the domains responsible for the antibacterial, chemotactic and LPS-binding activities of the 222 amino acid mature CAP37 protein (SEQ ID NO:9) as extracted from human neutrophils. Thus, it is an object of the present invention to provide bioactive peptides  
5 having at least 5 continuous amino acids derived from the above described sequence. These bioactive peptides are either chemotactic for monocytes, able to bind bacterial lipopolysaccharide and/or possess antibacterial qualities. The present invention further provides a recombinant process for the production of the bioactive peptides.

10 Additionally, it is an object of this invention to provide bioactive peptides (such as chemotactic, antibacterial and/or LPS-binding) derived from CAP37 that are capable of being produced in unlimited quantities and possess a non-infectious nature. Particularly advantageous are those bioactive peptides comprising the peptides shown in the Sequence Listing as SEQ ID NO:1, SEQ  
15 ID NO:3, SEQ ID NO:5, and SEQ ID NO:7 and those peptides comprising the peptides shown in the Sequence Listing as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8.

Another object of this invention is to provide bioactive peptides derived from CAP37 that possess enhanced bactericidal activity with respect to the  
20 mature CAP37 protein against both gram negative and gram positive bacteria.

Another object of the present invention is to provide expression vectors containing DNA sequences encoding any of the above protein or peptide sequences. These vectors are useful for introducing the coding sequences into suitable hosts. The expression vectors are effective to express the recombinant  
25 proteins in a variety of hosts, for example, bacteria, yeast, and mammalian cells. One vector useful for expression of the above described cationic granule protein contains a cytomegalo virus promoter and a polyadenylation signal from SV40, in addition to the dihydrofolate reductase gene to facilitate selection of the vector in the transformed host.

30 The invention further includes a method of treating a wound by the application of a topical medication containing a cationic granule protein (CAP37) having the amino acid sequence shown in the Sequence Listing as SEQ

ID NO:9, or proteins and/or peptides derived from CAP37 that are chemotactic for monocytes or possess antibacterial activity, in the medication in a pharmacologically effective amount to promote wound healing and/or treat infection. Other additions to the medication may be desirable such as the  
5 inclusion of epidermal growth factor also present in a pharmacologically effective amount to promote wound healing. The topical medication may take any number of standard forms such as pastes, gels, creams, and ointments. Additionally, the invention includes methods of treating tumors and other diseases using CAP37 and its related proteins and peptides.

10 It is an object of this invention to treat infection, especially infection caused by gram negative bacteria, by administration of an effective amount of a peptide derived from CAP37 having bactericidal activity superior to that of the mature CAP37 protein, most preferably by administration of the peptide defined in the Sequence Listing by SEQ ID NO:8.

15 Further, this invention provides for a method of treating endotoxemia or a prophylactic treatment, such as before surgery, for endotoxemia consisting of administration of an effective amount of the CAP37 mature protein or a peptide derived from CAP37 having LPS-binding activity.

The invention also includes hybrid proteins containing the cationic  
20 granule protein having the amino acid sequence shown in the Sequence Listing as SEQ ID NO:9 covalently attached to a second protein molecule, such as an antibody, ricin A chain, abrin A chain or trichosanthin.

These and other features of the invention will become more fully apparent when the following detailed description of the invention is read in  
25 conjunction with the accompanying examples.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the sequences of peptide fragments derived from the mature CAP37 protein as relevant to the Examples.

30 Figure 2 shows a plot of the data which demonstrates the chemotactic properties of the CAP37 protein.

Figure 3 shows the results of an ELISA showing binding of CAP37 to LPS and Lipid A.

Figure 4 shows a comparison of the N-terminal amino acid sequence of the CAP37 protein with several inflammatory cell proteases.

5      Figure 5 illustrates the pcDNAI cloning vector used for subcloning inserts from original lambda clones.

Figure 6 shows the nucleic acid and protein sequences of the first isolated cDNA insert having homology to CAP37 protein.

10      Figure 7 shows the nucleic acid and protein sequences of the 6a.1 clone insert.

Figure 8 shows a hydropathy index computation for the entire coding sequence of the CAP37 protein including: the amino-terminal extension and the sequence encoding the mature protein.

15      Figure 9 illustrates the expression vectors used for expression of CAP37 protein in mammalian cells.

Figure 10 depicts the elution profile of the eluates from the hydrophobic HPLC of the impure product obtained after separation on a SEPHADEX G-75 chromatographic column.

20      Figure 11 shows a plot of the data which demonstrates the chemotactic properties of peptides derived from the 114th to 122nd amino acid region of the mature CAP37 protein.

Figure 12 shows the bactericidal effect of peptides derived from the mature CAP37 protein on *Salmonella typhimurium* SH9178.

25      Figure 13 shows the bactericidal effect of peptides derived from the 1st to 44th amino acid region of the mature CAP37 protein on *Salmonella typhimurium* SH9178.

Figure 14 shows the bactericidal effect of the peptide 20-44aa (SEQ ID NO:8) derived from the mature CAP37 protein on various gram negative and gram positive bacteria.

30      Figure 15 shows a comparison of bactericidal activity of the peptide 20-44aa (SEQ ID NO:8) derived from the mature CAP37 protein against



*Salmonella typhimurium* SH9178 with peptides derived from similar regions from cathepsin G and elastase peptide.

Figure 16 shows the inhibition of the bactericidal effect of the peptide 20-44aa (SEQ ID NO:8) derived from the mature CAP37 protein on *Salmonella*  
5 *typhimurium* SH9178 by LPS and Lipid A.

Figure 17(A) shows the neutralization of wild type LPS activity and  
Figure 17(B) shows the neutralization of ReLPS by the peptide 20-44aa (SEQ ID NO:8) derived from the mature CAP37 protein as assayed by the limulus ameocyte lysate assay.

## DETAILED DESCRIPTION OF THE INVENTION

I. PURIFICATION AND CHARACTERIZATION OF THE HUMAN CAP37 PROTEIN5 A. *Purification and Sequencing of CAP37 Protein.*

CAP37 protein was purified from polymorphonuclear leukocytes (PMN) obtained from healthy adult donors (Example 1-A). The crude preparation generated from PMNs was dialyzed and applied to an ion exchange column. The eluent containing the CAP37 protein came off of the column at NaCl  
10 concentrations in the range of 0.6 to 0.7 M, as judged by SDS-PAGE of the fractions. This eluent was dialyzed and concentrated. The concentrated preparation was size fractionated and the fractions analyzed by SDS-PAGE to determine the fractions containing the CAP37 protein (Example 1).

Ascites fluid containing antibodies against CAP37 protein was prepared  
15 by injecting mice with alum-adsorbed CAP37 protein emulsified in Freund's complete and Freund's incomplete adjuvant (Example 1-C). The specificity of the ascites fluid reactivity against the CAP37 protein was demonstrated in ELISA assays using CAP37, CAP57 (a cationic antimicrobial protein of mol. wt. 57,000 Da; Spitznagel et al.), lactoferrin, myeloperoxidase, cathepsin G and  
20 lysozyme as the antigens.

Immunocytochemical analysis of normal human PMN using the monospecific polyvalent mouse antiserum to CAP37 established that CAP37 was a component of the cytoplasmic granules of human PMNs. All other peripheral blood cells which included eosinophils, monocytes, lymphocytes and red blood  
25 cells, did not stain positive for CAP37. Immunocytochemical analysis also demonstrated the presence of CAP37 in normal bone marrow, in cells belonging to the myeloid lineage, and in peripheral blood PMN from patients with chronic myelogenous leukemia (CML).

For chemotactic assays, the CAP37 protein was further purified by  
30 fractionation of the preparation using hydrophobic high performance liquid chromatography (HPLC). For amino acid sequence determination, a final desalting step was added utilizing reverse-phase HPLC (Example 1).

The N-terminal amino acid sequence of the CAP37 protein was determined by standard microsequencing procedures (Example 1-D). Figure 1 (Example 1) shows the peptide fragment sequences which were determined for part of the mature CAP37 protein. The first 42 amino acids at the amino terminus of CAP37 have received accession number A33070 from the Biomedical Research Foundation, Georgetown University Medical Center, Washington, D.C. 20007.

*B. Chemotactic and LPS-binding Properties of CAP37 Protein*

Chemotaxis assays were performed using the modified Boyden chamber technique (Example 2). The results (Figure 2) demonstrated that CAP37 was obviously chemotactic for human monocytes in the range of 10 to 10,000 pM. CAP37 appeared to be as effective as FMLP in attracting monocytes. These experiments suggest CAP37 did not have any effect on PMN and lymphocyte chemotaxis.

In addition to the observed chemotactic effect on human monocytes, CAP37 at a higher concentration of 1000 ng/ml ( $2.7 \times 10^{-8}$  M) was chemotactic for rabbit monocytes as well. This may reflect either (i) a reduction in the numbers of receptors for CAP37 on rabbit monocytes as compared to the number of receptors on human monocytes, or, (ii) a difference in the  $K_d$  values for the two species. The effect was selective for monocytes since, rabbit PMN did not show a chemotactic response towards CAP37.

One of the important aspects of identification of a chemotaxin is to distinguish directed cell movement (chemotaxis) through the filters as opposed to merely accelerated random motion (chemokinesis). Using the checkerboard assay (Example 2) it was demonstrated that, in addition to its chemotactic properties, CAP37 protein also has some chemokinetic effect on monocytes.

LPS-binding activity of the mature CAP37 protein was determined by measuring the LPS neutralization by CAP37 as determined by the Limulus Amebocyte Lysate (LAL) assay. CAP37 significantly neutralized LPS activity in the LAL assay. Further, ELISA shows binding of CAP37 to LPS; CAP37 is capable of binding LPS and, in particular, Lipid A (Figure 3).

C. *Protein Sequence Comparisons with the Amino Terminus of the CAP37 Protein.*

Using the amino terminal sequence of the CAP37 protein, a homology search was conducted of known protein sequences. This search revealed  
5 substantial homologies with the amino termini of a subset of serine proteases which mediate a number of functions involved in the inflammatory response (Figure 4).

Most of the serine proteases with which CAP37 protein shares its greatest homology (elastase, cathepsin G, rat mast cell proteases I and II, H Factor and  
10 cytotoxic T cell specific protein I) are derived from the granules of peripheral blood cells. Further, these homologous proteins are known to play important roles in inflammation, such as cytolysis or degradation of extracellular matrices.

Two other serine proteases, bovine thrombin (Bing et al.) and a trypsin-like protease in guinea pig plasma (Kawaguchi et al.), have been described  
15 which exhibit chemotactic activity. Further, Wright et al. have described the presence of a factor(s) in PMN specific granules which acts on serum to produce chemotactically active C5a and the opsonin C3b.

The experiments performed in support of the present invention show the isolation, characterization and purification to homogeneity of a PMN-granule  
20 associated protein which has monocyte specific chemotactic activity. Further, the CAP37 protein possesses LPS-binding activity as well as bactericidal activity and thus may perform three very important functional roles *in vivo*.

25

Example 1

Purification and sequencing of human CAP37 protein

A. *Source and Preparation of Peripheral Blood PMN and Monocytes*

Blood was collected into sterile sodium-EDTA tubes by venepuncture from healthy adult donors. The polymorphonuclear leukocytes (PMN) were  
30 separated from mononuclear cells essentially by the ficoll hypaque density gradient technique of Boyum, followed by dextran sedimentation (T500,

Pharmacia 3% in saline) and hypotonic lysis of contaminating red blood cells (RBC).

The mononuclear cell band was further purified to separate the monocytes from the lymphocytes. The mononuclear cells were washed once in  
5 phosphate buffered saline (PBS: 0.01 M  $\text{Na}_2\text{HPO}_4$ , containing 0.15 M NaCl, pH 7.4) and resuspended in PBS to a total volume of 5.1 ml. This cell suspension was then added to 6.7 ml of SEPRACELL-MN reagent (a colloidal, silica-based medium having a density of 1.099 g/ml, and available from Sepratech Corporation, Oklahoma City, Oklahoma), and centrifuged (1500 g for 20 min at  
10 22°C). The cells were washed twice in PBS (150 X g, 15 min) and resuspended in Geys buffered saline (Gibco) containing 2% bovine serum albumin (BSA - Fraction V, endotoxin free, Boehringer Mannheim Biochemicals) at a final concentration of  $2 \times 10^6$  cells/ml. (Geys buffer has the following composition:  
15  $\text{CaCl}_2$ (anhyd.) 0.17 g/L; KCl 0.37 g/L;  $\text{KH}_2\text{PO}_4$  0.03 g/L;  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$  0.21 g/L;  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$  0.07 g/L; NaCl 7 g/L;  $\text{NaHCO}_3$  2.27 g/L;  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$  0.226 g/L; D-Glucose 1.00 g/L.) The monocytes were greater than 95% pure as determined by Wright's and non-specific esterase staining.

Peripheral blood mononuclear cells from adult female rabbits, were separated on a 61% PERCOLL (Pharmacia) gradient (Chambers et al.). This  
20 technique separated the mononuclear cells from the RBC and PMNs. No further separation of monocytes from lymphocytes was undertaken with the rabbit blood.

#### B. *Purification of CAP37*

25 A granulocyte concentrate (>95% PMN) was obtained by leukaphoresis from a normal human donor. The PMN were disrupted by homogenization in a Potter-Elvehjem tissue grinder (Kontes) for 60 sec at 4°C. Mixed (specific and azurophil) granules were harvested by differential centrifugation. The supernatant obtained by centrifuging at 126 x g for 15 minutes was further  
30 centrifuged at 20,000 x g for 20 minutes to yield a pellet of mixed granules which was extracted at 4°C with 0.2M sodium acetate (pH 4.0). Granule debris was collected by high-speed centrifugation at 20,000 x g for 30 min. The protein

concentration was determined by the method of Bradford with chick egg white lysozyme as the standard (Bradford et al., 1976).

The crude granule extract was dialyzed against 50 mM sodium acetate (pH=5) and 0.15 M NaCl at 4°C overnight. The dialysate was then applied to a  
5 carboxymethyl SEPHADEX ion exchange column (a weakly acidic cation exchanger having sodium as a counter-ion and carboxymethyl as a functional group, and available from Pharmacia, Piscataway NJ) which had been equilibrated with 50 mM sodium acetate (pH=5) and 0.15 M NaCl. The column was extensively washed with 6M urea in 0.05M sodium acetate (pH5)  
10 containing 1.5M sodium chloride. Protein bound to the column was eluted using a two-step linear salt gradient consisting of 0.15 to 0.4 M and 0.4 to 1.0 M NaCl in 50 mM sodium acetate pH=5. Protein elution was monitored by measuring the absorbance of the eluent at 280 nm. Salt concentrations of the fractions were determined by conductivity measurements. Fractions from the CMS  
15 column were tested by ELISA using antiserum to CAP37 to determine those fractions which contained CAP37.

The positive fractions were pooled and dialyzed overnight against 0.2 M sodium acetate (pH=4) at 4°C, concentrated by membrane ultrafiltration at 4°C using a YM-5 membrane filter (an ultrafiltration membrane having very low  
20 non-specific protein binding properties, a nominal molecular weight cut-off of 5000 daltons, a clean water flow rate of 0.07 -0.1ml/min/cm<sup>2</sup> and available from Amicon Corp., Lexington KY). The concentrated preparation was applied to a SEPHADEX G-75 SF (Pharmacia) column (0.5 by 50 cm) which had been equilibrated with 0.2 M sodium acetate (pH=4). (SEPHADEX G-75 is a  
25 chromatographic medium comprised of a bead-formed gel prepared by cross-linking dextran with epichlorohydrin; said medium having a dry bead size of 10-40  $\mu$ , bed volume of 12-15 ml/g of dry SEPHADEX, and fractionation range for globular proteins and peptides of 3,000-70,000 daltons.) Fractions were eluted using the equilibration buffer and the A<sub>210</sub> of each fraction determined.  
30 The fractions were analyzed by ELISA and by SDS-PAGE to determine the fraction containing the CAP37 protein.

The CAP37-enriched fraction obtained from the molecular sieve column was further processed using hydrophobic high performance liquid chromatography (HPLC) (BIO-GEL TSK phenyl 5PW column, 7.5 mm x 0.75mm, packed with a 10 micron macroporous support having 1,000 angstrom pores and containing a low density of phenyl groups which promote strong but nondenaturing hydrophobic interactions with proteins, said column available from Biorad Laboratories). The proteins were eluted using a 60 min linear gradient from 1.7 M to 0 M  $(\text{NH}_4)_2\text{SO}_4$ , which contained 0.1 M sodium phosphate pH 7.0. The recovery was determined by the optical density of the proteins at 210 nm. The fractions obtained from the hydrophobic HPLC column were pooled independently and the  $(\text{NH}_4)_2\text{SO}_4$  removed by dialysis employing a stirred cell concentrator (YM-5 membrane, Amicon) with 0.2 M sodium acetate buffer, pH= 4.0.

The purity of the fractions was determined by SDS-PAGE, western blot analysis and ELISA. All these results confirm that CAP37 prepared in this manner is devoid of other contaminating granule proteins which include the defensins, cathepsin G, myeloperoxidase, lactoferrin, and CAP57, and thus indicates that the outlined method yields a highly purified preparation of CAP37.

An important aspect of the production of CAP37 was to keep it free from endotoxin contamination. All reagents and buffers were prepared using pyrogen-free water and tested for endotoxin contamination using the Limulus amoebocyte assay (Whittaker Products). All glassware used was pyrogen-free. The starting material for each column was always checked for endotoxin contamination before it was applied to the column and, most importantly, the final product was always checked for the presence of endotoxin before use.

As seen in Figure 10, the elution profile from the hydrophobic HPLC column indicated the presence of two proteins. CAP37 was confined to Peak 2, the more hydrophobic peak. Peak 1 was found to contain cathepsin G, as judged by SDS-PAGE.

SDS-PAGE was performed to depict the stages of purification of CAP37 from normal human crude granule extract (CGE). The analysis was performed

according to the method described by Laemmli (1970). The samples were solubilized in 0.625M Tris (pH 6.8), 4% (w/v) SDS, and 1% (v/v) beta mercapto ethanol, at 100°C for 5 min and analyzed on a 12.5% gel essentially according to the method of Laemmli. The analysis was performed under reducing conditions  
5 with a 12.5 % separating gel and a 4% stacking gel as described by Laemmli. The ratio of the acrylamide to the bisacrylamide was 37.5. Electrophoresis was carried out until the bromophenol blue dye reached the bottom of the separating gel. The gel was removed and fixed in a 25% isopropanol, 7% acetic acid mixture. The gel was oxidized and stained with silver to visualize the  
10 protein bands.

The gel was silver stained according to well established protocols. Lane 1 contained 2  $\mu$ g "rainbow" molecular weight markers (Amersham). Lane 2 contained 5  $\mu$ g of crude granule extract (CGE). Lane 3 contained 400 ng of peak C material obtained from the G-75 column which served as the starting  
15 material for the HPLC column. Lane 4 contained 350 ng of peak 2 (CAP37) from the HPLC column. Lane 5 contained 350 ng of peak 1 from the HPLC column and lane 6 contained purified cathepsin G. The molecular weight standards used included myosin ( $M_r$  200,000), phosphorylase b ( $M_r$  92,500), bovine serum albumin ( $M_r$  69,000), ovalbumin ( $M_r$  46,000), carbonic anhydrase  
20 ( $M_r$  30,000), trypsin inhibitor ( $M_r$  21,500) and lysozyme ( $M_r$  14,300).

The CAP37 material from peak 2 (lane 4) migrated in SDS-PAGE as three extremely closely spaced bands with a molecular weight near 37,000 daltons. This electrophoretic behavior probably indicates glycosylation of the protein, rather than any heterogeneity of the protein preparation. Furthermore,  
25 the fact that this preparation yielded an unambiguous amino acid sequence would also tend to indicate the absence of heterogeneity.

Judging from the nearly identical migration patterns of peak 1 from the HPLC Column (lane 6) and cathepsin G (lane 5), it may be concluded that this peak 1 material is cathepsin G. This was confirmed by the western blots.

30 The fractions obtained from the HPLC column were also analyzed by western blots. Western blot analysis was carried out according to the method of Towbin et al. (1979) with some modifications. Following electrophoresis on a



12.5 % SDS-PAGE gel, the proteins were transferred onto a nitrocellulose membrane (Biorad, Richmond, CA) in a TE series, Transphor Electrophoresis Unit (Hoefer Scientific Instruments, CA) under constant current (200 mA) at 11°C for 1.5 hr. The concentration of the methanol in the buffer was reduced  
5 from 20% to 5% (v/v) and the pH raised to 9. The protein was detected on the nitrocellulose membrane using a mouse antibody to CAP37 (1: 100 dilution) and an alkaline phosphatase immunoblotting system with the addition system of 10 units per ml heparin sulfate buffer (Eastman, Kodak) (Spitznagel et al., (1987)) in the wash buffer (0.15 M NaCl, 0.01M Tris HCl (pH 7.5), 0.01% v/v TWEEN  
10 20). Color development was obtained with the nitroblue tetrazolium/BCIP system.

The results of the western blot confirmed the SDS-PAGE results. Lane 1 contained molecular weight markers as described for the SDS-PAGE. Lanes 2 and 6 contained crude granule extract. Lanes 3 and 7 contained peak C  
15 material from the G-75 column. Lanes 4 and 8 contained peak 2 from the HPLC column and lanes 5 and 9 contained peak 1 from the HPLC column. The protein concentrations of all the samples loaded onto the gel were the same as described above.

Lanes 1 to 5 were probed with goat anti-human cathepsin G (1:2000  
20 dilution) and lanes 6 to 9 were probed with mouse anti-human CAP37 (1: 100 dilution). The second antibody was conjugated to alkaline phosphatase (1: 7500 dilution, Promega). Color development was obtained using the nitroblue tetrazolium/ BCIP system as outlined in the manufacturers handbook (Promega). The goat anti-human cathepsin G antiserum reacted with crude granule extract,  
25 peak C material and peak 1 from the HPLC column. It did not react with CAP37 (peak 2 material from the HPLC column). On the other hand, the antiserum to CAP37 reacted with peak 2 material but not with the cathepsin G. This indicates that CAP37 was totally separated from the contaminating  
cathepsin G in the final step of the purification which is performed on the  
30 hydrophobic HPLC column.

The proteins obtained from the HPLC column were further analyzed by ELISA which confirmed the purity of the CAP37 preparation. The ELISA

method used is described in Pereira, et al., (1989), and has proven to be a reproducible and sensitive method for the detection of cationic proteins. Briefly, the protein was attached to a 96 well microtitre plate (NUNC Immunoplate I, VWR Scientific) which was pre-treated with poly-L-lysine. Following an  
5 overnight incubation at 4°C, the plate containing the antigen was washed four times in phosphate buffered saline (pH 7.4). Non-specific sites on the plate were then blocked with a heparin containing phosphate buffer, at room temperature for 1 hr (Pereira et al., 1989). The plates were washed and the primary antibody was then added to the plate and incubated for 1 hr at 37°C.  
10 Following this incubation the plate was washed and the second antibody was added and the plate incubated for 1 hr at 37°C. The second antibody was a goat anti-mouse immunoglobulin which is conjugated to horse-radish peroxidase. The color development step involves incubating the substrate (3.7 mM 0-phenylenediamine) in citrate phosphate buffer, pH 5.0, containing 0.24  $\mu$ l/ml  
15 30% H<sub>2</sub>O<sub>2</sub> at room temperature for 30 min. The reaction is stopped with 2.5 M H<sub>2</sub>SO<sub>4</sub> and the absorbance read immediately using a TITERTEK multiscan plate reader (Flow Laboratories) at 492 nm.

The results of the ELISA confirmed the results of the other analyses.

The same samples as used for the SDS-PAGE were also used in the ELISA.

20 Primary antibodies were prepared against each of these samples. The material from Peak 2 reacted only with the antibodies prepared against a pure CAP37, while the material from Peak 1 reacted with the antibody prepared against Cathepsin G. The crude granule extract reacted with all the antibodies and the Peak C material reacted with antibodies for CAP37 and for Cathepsin G.

25 For amino acid sequencing of the CAP37 protein a final desalting step using reverse phase HPLC was employed. A DYNAMAX 300A C8 column was equilibrated with 0.1% Trifluoroacetic acid in water the above-purified material was then applied to the column. Elution of the purified protein was effected by a 30 minute elution with a 0-80% gradient of 0.1% Trifluoroacetic acid in  
30 acetonitrile at a flow rate of 1 ml per minute. The CAP37 protein containing sample corresponded to the 16.14 minute peak, as determined by SDS-PAGE: this fraction was concentrated in a Savant Instruments SPEED VAC.

C. *Antibodies to Purified CAP37 Protein*

Ascites fluid containing antibodies against CAP37 protein was prepared by injecting BALB/c mice (Jackson Laboratories) with 250 ng of alum-adsorbed (Herbert) CAP37 protein emulsified in an equal volume of Freund's complete and Freund's incomplete adjuvant (Difco Laboratories). Mice were subcutaneously injected with a total volume of 200  $\mu$ l of the above suspension. The mice were boosted three weeks later with 250 ng of alum-adsorbed CAP37 injected intraperitoneally. At the same time the mice were injected with 1 ml of pristane (2,6,10,14 - tetramethyl pentadecane, Sigma). One week later 10<sup>7</sup> SP2/0 mouse myeloma cells were injected intraperitoneally (Lacy et al.). Ascites fluid was collected. The specificity of the ascites fluid reactivity against the CAP37 protein was demonstrated in ELISA assays (Pereira et al.) using CAP37, CAP57 (a cationic antimicrobial protein of mol. wt. 57,000 Da; Spitznagel et al.), lactoferrin, myeloperoxidase, cathepsin G and lysozyme as the antigens. Further, no cross reactivity between Cathepsin G and CAP37 protein was observed by western blot analysis (Ausubel et al.).

For the immunocytochemical studies, the final cell concentration was adjusted to 1 x 10<sup>6</sup> nucleated cells per ml in 10% heat inactivated fetal bovine serum (Hyclone Laboratories Inc., Utah) in PBS. One hundred microlitres of the cell suspension was cytocentrifuged onto glass slides. The cells were fixed in buffered formol acetone, pH 7.2 at 4°C for 60 seconds. The staining was performed using the VECTASTAIN Avidin Biotin Complex - Glucose oxidase (ABC-G0) technique (Vectastain Laboratories, Burlingame, CA) as described previously (Spitznagel et al.). The above described monospecific polyvalent mouse anti CAP37 ascites fluid (1:100) was used to stain the cells. Color development was obtained using the nitroblue tetrazolium salt (VECTASTAIN GO substrate kit I) at room temperature for 30 minutes. Normal mouse serum and phosphate buffered saline (PBS) served as the negative controls. Ascites fluid made against myeloperoxidase, a known marker of the primary granule of PMNs, served as the positive control.

#### D. *Microsequencing of CAP37*

The protein sequence analysis of CAP37 was performed using an Applied Biosystems Model 477A Protein/Peptide Sequencer with an on-line Applied Biosystems 120A PTH-Amino Acid Analyzer. Reagents and solvents were from Applied Biosystems, Foster City, CA. Phenylthiohydantoin (PTH)-derivatized amino acids formed sequentially by Edman degradation were separated using an Applied Biosystems PTH C-18 HPLC reverse phase microbore column (2.1 mm ID x 220 mm) by gradient elution. The sample was applied to an acid-etched glass-fiber filter which had been treated with 3 mg Biobrene (polybrene) and precycled. Peak identification and yield quantitation was based on a standard PTH-amino acid profile. The N-terminal end of the CAP37 protein was identified by standard microsequencing procedures (Applied Biosystems). Trypsin and chymotrypsin generated digestion fragments of CAP37, were separated and purified using hydrophobic and reverse-phase HPLC (Example 1-B). These fragments were then sequenced, as described above. When the cloning of the cDNA was undertaken only the sequences shown in Figure 1 had been determined. The sequences of the amino and carboxy termini of the mature CAP37 protein are designated in Figure 1.

#### Example 2

##### Chemotactic and LPS-binding Properties of the Purified Human CAP37

#### A. *In Vitro Chemotaxis Assays*

Chemotaxis was measured using the modified Boyden chamber technique (Snyderman et al.). The leading front method (Zigmond et al.) was used to assess migration of monocytes and lymphocytes through a 8  $\mu$ m filter (Millipore Corporation, Bedford, MA). PMN chemotaxis was measured using a 3  $\mu$ m filter (Millipore). The purified CAP37 protein (Example 1) used in chemotaxis assays were endotoxin-free as determined by the Limulus Amoebocyte Lysate Assay (Whittaker Bioproducts, Inc., Walkersville, MD). The dilutions of CAP37 and N-formyl-methionyl-leucyl-phenylalanine (FMLP) were made in Geys buffer (Gibco) containing 2% endotoxin-free bovine serum albumin (BSA). Geys

buffer containing 2% BSA served as the negative control, and a  $10^{-8}$  M solution of FMLP as the positive control.

The chambers were incubated in a humidified atmosphere (6.2% CO<sub>2</sub>) for 2 hours when testing monocytes and lymphocytes, and for 30 minutes when testing PMNs. The filters were then removed and processed as previously described (Snyderman et al.). The cells were viewed using oil immersion and the distance the cells had migrated into the filter was determined over five different fields on the same slide (Zigmond et al.). Triplicate assays were performed for each experimental point.

The results are presented in Figure 2. The data clearly show the strong chemotactic properties of the CAP37 protein.

CAP37 did not have any effect on PMN and lymphocyte chemotaxis in the range employed in these experiments. In addition to the observed chemotactic effect on human monocytes, CAP37 at a higher concentration of 1000 ng/ml ( $2.7 \times 10^{-8}$  M) was chemotactic for rabbit monocytes as well. The effect was selective for monocytes since rabbit PMN did not show a chemotactic response towards CAP37.

To distinguish directed cell movement (chemotaxis) through the filters of a Boyden chamber as opposed to accelerated random cell motion (chemokinesis), the chemokinetic activity of CAP37 was determined by the checkerboard assay of Zigmond et al. The checkerboard assay demonstrated that in addition to its chemotactic properties, CAP37 has some chemokinetic effect on monocytes.

Figure 3 shows the results of an ELISA procedure used for determining the binding of CAP37 to LPS from *S. minnesota* wild type (diamonds); LPS from *S. minnesota* Re mutant (triangles); Lipid A from *S. minnesota* R595 (circles); and Lipid A from *S. typhimurium* Re mutant (squares). The LPS from *S. minnesota* wild type, *S. minnesota* Re mutant, Lipid A from *S. minnesota* R595, and Lipid A from *S. typhimurium* Re mutant were applied to microtitre wells at concentrations ranging from 0 to 50 µg/ml and incubated overnight. The trays were then incubated with CAP37 at 120 ng/well for 1 hour at 37°C. The next incubation was with a rabbit antiserum against CAP37 (1:400 dilution) and the

color development was as previously described (Pereira et al., 1989) and the absorbance was read at 492 nm. The results shown in Figure 3 indicate that CAP37 is capable of binding Re LPS and, in particular, is able to bind to Lipid A better than wild type LPS.

5 Further, the neutralization of LPS activity, as assayed by the limulus amebocyte lysate (LAL) assay, by CAP37 was measured. CAP37 was diluted to the desired concentrations (from 6.2 ng/ml to 500 ng/ml) in geys buffered saline pH 7 (GIBCO). To this wild type LPS (RIBI IMMUNOCHEM) or Re LPS from *Salmonella* (David Morrison, Kansas Medical Center) was added so that  
10 the final concentrations were 0.1, 0.5, 1.0 and 2.0 ng/ml LPS. The tubes were incubated at 37°C for between 30 to 60 minutes and then assayed in the chromogenic LAL assay, using polymyxin E as a control. CAP37 significantly neutralized LPS activity in the LAL assay.

#### 15 B. *In Vivo* Chemotactic Assay

The purpose of these experiments is to document that CAP37 when injected *in vivo* into mice will result in the emigration of monocytes/macrophages.

Female BALB/c mice (6 - 8 weeks) (Jackson Laboratory, Bar Harbor,  
20 MI) were injected intraperitoneally (i.p.) with 100 ng CAP37 (purified according to the method of the invention) per mouse in 2 ml RPMI-1640 serum-free medium (Mediatech). A control group of mice were injected i.p. with 2 ml brewers thioglycollate (4% w/v) (Difco Laboratories), a known stimulator of inflammatory cells whose action is well documented. A second control group of  
25 mice were injected i.p. with 2ml of RPMI-1640 alone.

(RPMI-1640 serum free medium from Mediatech has the following composition: CaNO<sub>3</sub>·4H<sub>2</sub>O:100.00mg/L; KCl:400.00mg/L; MgSO<sub>4</sub>·7H<sub>2</sub>O:100.00mg/L; NaCl:6000.00mg/L; NaHCO<sub>3</sub>:2000.00mg/L; Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O:1512.00mg/L; D-Glucose:2000.00mg/L; Glutathione  
30 (reduced):1.00mg/L; Phenol red:5.00mg/L; L-Arginine(free base):200.00mg/L; L-Asparagine:50.00mg/L; L-Aspartic acid:20.00mg/L; L-Cystine:50.00mg/L; L-Glutamic acid:20.00mg/L; L-Glutamine:300.00mg/L; Glycine:10.00mg/L;

L-Histidine (free base):15.00mg/L; L-Hydroxyproline:20.00mg/L;  
L-Isoleucine (Allo free):50.00mg/L; L-Leucine (Methionine free):50.00mg/L;  
L-Lysine HCl:40.00mg/L; L-Methionine:15.00mg/L; L-Phenylalanine:15.00mg/L;  
L-Proline (Hydroxy L-Proline free):20.00mg/L; L-Serine:30.00mg/L; L-Threonine  
5 (Allo free):20.00mg/L; L-Tryptophan:5.00mg/L; L-Tyrosine:20.00mg/L;  
L-Valine:20.00mg/L; Biotin:0.20mg/L; D-Ca pantothenate:0.25mg/L; Choline  
chloride:3.00mg/L; Folic acid:1.00mg/L; i-Inositol:35.00mg/L;  
Nicotinamide:1.00mg/L; Para-aminobenzoic acid:1.00mg/L; Pyridoxine  
HCl:1.00mg/L; Riboflavin:0.20mg/L; Thiamine HCl:1.00mg/L; and Vitamin  
10 B<sub>12</sub>:0.005mg/L.)

At 6, 24, 48 and 72 hours following these i.p. injections, four mice in each group were sacrificed by CO<sub>2</sub> anesthesia. Ten ml sterile medium was injected into the peritoneal cavity of each mouse and the abdominal area gently massaged to dislodge the exudate cells. The medium containing the exudate  
15 cells was then aspirated from the peritoneal cavity using a 19 gauge needle attached to a syringe. The total number of cells in the peritoneal exudate was determined by counting the cells on a COULTER COUNTER (Coulter Electronics, Hialeah, Florida: The operation of the COULTER COUNTER is based on electrical conductivity difference between particles and common  
20 diluent. Particles act as insulators, diluents as good conductors. The particles, suspended in an electrolyte, are forced through a small aperture through which an electrical current path has been established. As each particle displaces electrolyte in the aperture, a pulse essentially proportional to the particle volume is produced. Thus a 3-dimensional particle volume response is the basis  
25 for all sizing, regardless of position or orientation of the particle in solution.) One hundred  $\mu$ l of the peritoneal exudate was cytocentrifuged onto a glass slide and the cells stained with Wright's stain. A differential count of the cells was made by counting the number of monocytes, lymphocytes, neutrophils, basophils and eosinophils per hundred consecutive cells. These experiments were  
30 performed to determine the time course of migration of neutrophils, monocytes, lymphocytes and other cells into the peritoneal cavity, in response to an i.p. injection of CAP37.

Traditionally neutrophils are the first cells to migrate into the peritoneal cavity, and they do so about 6 hours after the i.p. injection. Monocytes emigrate much later, generally 72 hours to 6 days after the i.p. injection.

The results, shown in Table 1 below, indicated that an injection of 100 ng of CAP37 into the peritoneal cavity, moderately increased the overall numbers of cells emigrating into the peritoneal cavity. Nevertheless, monocytes appeared in the peritoneal cavity much earlier (24 hours) than when thioglycollate was used. Furthermore, the percentage of monocytes elicited with CAP37 (55%) was much greater than when sodium thioglycollate (33%) was used even at the 72 hour time point. A further interesting observation was the dramatic reduction in neutrophils by 24 hours with the CAP37 injection whereas, with thioglycollate, the neutrophils persist at a very high percentage up to 48 hours (36%), and are still present at 72 hours (21%).

TABLE 1: Migration of cells following intraperitoneal injection with the inflammatory stimulus indicated.

Inflammatory Stimulus <sup>a</sup>	Hours Post Injection	Total Cells <sup>b</sup> x 10 <sup>6</sup>	% monocytes	%PMN
None	0	3.1	18	30
RPMI-1640	6	1.5	15	42
	24	2.2	12	11
	48	3.1	14	28
	72	2.8	43	5
Thioglycollate	6	9.5	4	65
	24	9.1	5	77
	48	8.4	20	36
	72	11.1	33	21
CAP 37	6	3.6	7	65
	24	3.8	27	26
	48	3.5	48	4
	72	3.3	55	3

<sup>a</sup> Four mice per group

<sup>b</sup> Mean value for each group of four mice



These responses with CAP37 contrasted markedly with responses to endotoxin in which far greater cell numbers are found to endotoxin in which far greater cell numbers are found and PMN persist as the predominant cell type for at least 48 hours (Snyderman et al, (1971)). The migration of monocytes  
5 into the peritoneal cavity following CAP37 injection into the peritoneal cavity of mice demonstrates the potent monocyte chemoattractant capacity of CAP37 in this *in vivo* animal model.

### Example 3

#### 10 Comparison of the CAP37 protein amino terminal sequence

Using the first 45 amino acids of the amino terminal end of the CAP37 protein, a search of a protein sequence data base was made using the FASTAMAIL program through the BIONET network. This search revealed substantial homologies with the amino termini of a subset of serine proteases  
15 which mediate a number of functions involved in the inflammation response (see Figure 4: elastase, ELAST; complement factor D, FACTD; bovine plasminogen, PLASM; cathepsin G, CATG; rat mast cell protease I and II, RMCPI and RMCPII; cytotoxic T cell I, CCPI; cytotoxic T cell protease -- H Factor, HF).

The closest over-all homologies were obtained with two PMN-derived  
20 granular proteins: a homology of 57.5% with human elastase (Sinha et al.) also known as medullasin (Okano et al.) and a homology of 45% with human cathepsin G (Salvesen et al.). Other specific homologous sequences were seen with bovine plasminogen (45%) and human complement factor D (45.5%) (Johnson et al.; Nieman et al. et al.), which is the first enzyme involved in the  
25 activation of the alternative complement pathway.

Two other groups of proteins which demonstrated strong homology with the CAP37 protein were: (a) the group of serine protease-like molecules derived from granules of atypical rat mast cells -- rat mast cell protease I (Woodbury et al.), RMCPI, 38.6%, and rat mast cell protease II, RMCPII, 40% (Benfey et  
30 al.); and (b) two proteins from cytotoxic T cells -- cytotoxic T cell protease I (Lobe et al.), CCPI, 40%, and cytotoxic T cell protease factor H (Gershenfeld et al.), HF, 38.6%.

II. CLONING OF THE CAP37 PROTEIN CODING SEQUENCE:  
ISOLATION OF A FIRST cDNA HAVING HOMOLGY TO  
CAP37 PROTEIN.

For the isolation of the CAP37 cDNA coding sequence, poly-A mRNA  
5 was isolated from tumor cell line HL60 (Example 4-A,B). Using the CAP37  
protein specific antibodies generated in Example 1, the HL60 cell line was  
shown to contain antigens which reacted with this antibody. Double-stranded  
(ds) cDNA was generated from the isolated RNA molecules (Example 4-C,D).  
These ds molecules were cloned into the vector lambda-gt10 (Example 4-E).  
10 Plaques resulting from recombinant phage were transferred to duplicate  
filters and the filters hybridized with two CAP37 sequence specific probes  
(Example 4-E). The probes were non-coding strand 20-mer degenerative sets  
generated from the known amino terminal protein sequence of CAP37 protein  
(Figure 1, Example 1) based on the use of preferred human codons (Maruyama  
15 et al.). The filters were then probed with each probe set. The duplicate filters  
showed one recombinant plaque that was convincingly positive with both probes.

The phage was purified from the plaque which tested positive and the  
double-stranded cDNA insert was isolated from the phage. This insert was then  
cloned into vector pcDNAI (Example 5, Figure 5) and the insert sequenced.  
20 The complete sequence of this first cDNA clone is shown in Figure 6.

The nucleic acid sequence of the cDNA was translated into the  
corresponding protein sequences in all three frames. One of the reading frames  
showed significant alignment to the CAP37 protein sequence with the following  
exceptions: (i) the cloned sequences indicate that the encoded protein most  
25 likely has a precursor form since the cloned sequences contain an additional 48  
amino acids 5' to and in frame with the open reading corresponding to the  
CAP37 protein sequence (Example 6); (ii) there appeared to be some carboxy  
terminal differences in protein sequence; and, (iii) 19 amino acids present in a  
CAP37 protein fragment amino acid sequence were not found in the nucleic  
30 acid insert sequence (Example 6). The 19 amino acids missing from the protein  
encoded by the first cDNA clone suggested that although this clone contained  
coding sequences for the majority of the CAP37 protein it was not the correct  
cDNA.

Hybridization of other CAP37 specific probes to the above filters did not result in the identification of any more likely candidate plaques.

In order to clone a cDNA encoding the complete CAP37 protein sequence, the following strategy was employed. A specific DNA fragment, which would span the region where the discrepancy between the cDNA sequence and the protein sequence was observed (Example 6), was amplified (Example 7). One end of this DNA fragment was chosen to correspond to the amino acid sequence CQVAGWG (SEQ ID NO:11) (underlined in the CAP37 peptide sequence presented in Example 6): a degenerate 20-mer oligonucleotide probe (designated Intrlc) was designed to correspond to these amino acids.

The second end of the above discussed DNA fragment was less stringently designated. A number of non-degenerate 20-mer primers were designed from the sequence of the non-coding strand of CAP37 first cDNA which was 3' to the end of the site where the nucleic acid sequence diverged from the protein coding sequence (see \* in the CAP37 first cDNA sequence in Example 6).

Total human genomic DNA was used as template in DNA amplification reactions utilizing the above described primers (Example 7). The products of the amplification reactions were split into two samples, fractionated on an agarose gel and then one-half of the gel containing a complete set of samples was transferred to a nitrocellulose filter. The filter was then probed with the radioactively-labeled CAP37 first cDNA: one positive band was detected. The DNA was extracted from the region of the second half of the agarose gel corresponding to the positive band. This DNA fragment (Intrlc/669nc) was then sequenced (Example 7-A).

A 50-mer probe corresponding to a region of the Intrlc/669nc sequence which was not present in the CAP37 first cDNA clone was synthesized. This probe was then used to screen 200,000 plaques generated from the lambda-HL60 cDNA library (Example 7-B). After a secondary screen 5 plaques remained clearly positive. One of these clones, designated 6a.1, was sequenced using dideoxy sequencing. The complete DNA sequence of the 6a.1 clone is illustrated in Figure 7.

The DNA sequence corresponding to clone 6a.1 was translated in all three reading frames. One reading frame aligned with the amino acid sequences of the CAP37 peptide fragments determined in Example 1. The CAP37 mature protein coding sequence was preceded, in frame, by 26 amino acids, and had a short carboxy terminal extension. These results indicate that the 6a.1 clone is a complete cDNA clone encoding the CAP37 protein.

The first approximately 20 amino acids of the cDNA encoded CAP37 protein have a high degree of hydrophobicity (Figure 8). This sequence has the length and hydrophobicity of a typical eucaryotic secretory signal sequence (Example 8). The remaining amino acids in this 26 amino acid sequence and/or the carboxy-terminal extension may be involved in further cellular processing of the CAP37 protein or they may represent an inactive precursor form of the protein.

The portion of the open reading frame corresponding to the mature form of the CAP37 protein has an estimated molecular weight of 24,276 kilodaltons. Previously Shafer et al. (1986) determined the molecular weight of the CAP37 protein to be approximately 37,000 daltons. This discrepancy is most likely the result of post-translational modification, e.g. glycosylation, of the CAP37 protein.

Subsequent to the isolation and sequencing of the 6a.1 cDNA insert, the complete protein sequence of the mature CAP37 protein was determined. With the exception of the above described amino and carboxy terminal extensions, the coding sequence of the mature CAP37 protein exactly aligns with the protein sequence encoded by the 6a.1 insert.

25

#### Example 4

##### Isolation of a First cDNA having Homology to Human CAP37 Protein

###### A. *Preparation of poly-A mRNA*

The starting material for the isolation of human CAP37-encoding cDNA was tumor cell line HL60 (ATCC CCL240). Using the anti-CAP37 specific antibodies that were described above, the presence of an antigen reacting with these antibodies was shown to be present in the HL60 cell line: this cell line

was chosen as the starting material for cloning a CAP37 encoding cDNA. All of the following procedures were carried out on ice and with RNase-free materials.

Monolayers of HL60 were grown to confluence using standard sera-supplemented minimal media (DMEM/10% Fetal Calf Serum, 50 units/ml penicillin and 50  $\mu$ g/ml streptomycin) in 85 mm plates. Cells were grown to a density of  $10^6$  cells/ml. Each plate was placed on ice and washed four times with ice-cold phosphate buffered saline (PBS) and a final 2 ml aliquot of PBS added to each plate. The cells were harvested from each plate by scraping, transferred by pipette to COREX centrifuge tubes, and held on ice. When all the plates were harvested the cells were pelleted by centrifugation at 2000 X g for 5 minutes at 4°C.

RNA was isolated from  $10^8$  cells by the previously described method of Chirgwin et al. using guanidine isothiocyanate.

15 B. *Selecting the poly(A) enriched mRNA fraction.*

Oligo(dT) cellulose (0.1-1.0 g; purchased from Pharmacia) was suspended in 1-5 ml of elution buffer (distilled H<sub>2</sub>O, 1mM EDTA), poured into a 1- to 4-ml disposable column, and washed with 5 column volumes of binding buffer (0.01 M Tris-HCl at pH 7.5, 0.5 M NaCl, 1 mM EDTA, 0.5% SDS). The isolated RNA was resuspended at 1-5 mg/ml in elution buffer, heated to 65°C for 5 min, quickly cooled in ice, diluted with an equal volume of 2X binding buffer, and applied to the column: the flow-through was collected and reapplied to the column. The column was washed with 5-10 volumes of binding buffer and 5 volumes of wash buffer (0.01 M Tris-HCl at pH 7.5, 0.1 M NaCl, 1 mM EDTA).

The bound RNA was eluted with 2-3 column volumes of elution buffer; subsequently, it is adjusted to a final concentration of 0.5 M NaCl (with 5 M NaCl or 2X binding buffer), re-bound, re-washed, and re-eluted as described above. The RNA in the final eluate was recovered by addition of 0.1 volumes of 3 M sodium acetate and precipitation with 2.5 volumes of ethanol. Sodium dodecyl sulfate (SDS) is deliberately excluded from the wash and elution buffers to avoid precipitating the detergent from ethanol along with the RNA.

The final RNA sample was precipitated and dissolved in sterile water to a final RNA concentration of approximately  $1\mu\text{g}/\mu\text{l}$

C. *First-Strand cDNA Synthesis*

5 Double-stranded (ds) cDNA was synthesized using the Amersham cDNA synthesis kit. Briefly,  $5\mu\text{g}$  of mRNA was added to the following reaction mixture: first strand synthesis reaction buffer, sodium pyrophosphate solution, human placental ribonuclease inhibitor (HPRI, 50 units), deoxynucleotide triphosphate mix (1 mM dATP, 1 mM dGTP, 1 mM dTTP, and 0.5 mM dCTP),  
10  $4\mu\text{g}$  oligo-dT, 100 units reverse transcriptase, and  $5\mu\text{Ci}$  ( $\alpha\text{-}^{32}\text{P}$ )-dCTP in a total volume of  $50\mu\text{l}$ . The reaction was incubated at  $42^\circ\text{C}$  for 60 minutes.

D. *Second-Strand cDNA Synthesis*

A final volume ( $250\mu\text{l}$ ) containing the first strand synthesis mix was mixed  
15 with *E. coli* ribonuclease (4 units) and *E. coli* DNA polymerase I (115 units). This mixture was incubated at  $12^\circ\text{C}$  for 60 minutes,  $22^\circ\text{C}$  for 60 minutes, and  $70^\circ\text{C}$  for 10 minutes.  $T_4$  DNA polymerase (10 units) was added and the sample incubated at  $37^\circ\text{C}$  for 10 minutes. The ds cDNA was phenol/chloroform  
20 extracted, chloroform extracted, and ethanol precipitated (Maniatis et al.).

E. *Cloning of the Double Stranded cDNA.*

For ease of manipulation the double stranded cDNA was tailed with *EcoRI* linkers in the following manner.

The cDNA was resuspended in water and treated with *EcoRI* methylase  
25 under the following conditions: 100 mM Tris HCl, pH=8.0; 10 mM EDTA;  $80\mu\text{M}$  S-adenosyl-methionine;  $100\mu\text{g}/\text{ml}$  bovine serum albumin; with approximately 100 units of *EcoRI* methylase (Promega) in a total volume of  $50\mu\text{l}$  incubated at  $37^\circ\text{C}$  for 60 minutes. The cDNA was then precipitated with ethanol.

The cDNA was resuspended in  $5\mu\text{l}$  of  $\text{dH}_2\text{O}$  to which was added  $2\mu\text{l}$  of  
30 10x ligase buffer (0.5M Tris HCl, pH=7.4; 70mM  $\text{MgCl}_2$ ; 10 and  $1\mu\text{l}$  t4 DNA ligase (100 units). The mixture was incubated at  $16^\circ\text{C}$  overnight. The reaction mixture was extracted once with phenol/chloroform and the cDNA precipitated

with ethanol. The cDNA was then digested with *EcoRI* in a buffer containing 100 mM Tris-HCl (pH 7.5), 50 mM NaCl and *EcoRI* restriction enzyme (50 units) was incubated at 37°C for 3 hours. The ds cDNA was extracted, precipitated, resuspended, and separated from the *EcoRI* linkers using a  
5 Sephacryl S-400 column.

Finally, the cDNA was size fractionated as follows before insertion into the vector. The cDNA was resuspended in the following buffer: 0.6 M NaCl, 20 mM Tris HCl (pH=8.0), and 20 mM EDTA. This sample was then loaded on a SEPHACRYL S-400 column which was equilibrated with the same buffer. Fifty  
10 microliter aliquots were then collected and assayed by electrophoresis through an alkaline agarose gel to identify the fractions containing labelled cDNA molecules of greater than 400 base pairs (bp) in length. These >400 bp fractions were then pooled and the cDNA precipitated with ethanol.

The vector for insertion of the >400 bp cDNA molecules was *EcoRI*  
15 digested and phosphatased  $\lambda$ gt10 (Stratagene). A Stratagene Gigapack Gold Packaging Extract Kit was used to package the Lambda gt10/cDNA ligation mixture. A primary titer of  $1 \times 10^7$  PFU's was obtained.

Plaques resulting from recombinant phage, carrying the cDNA, were then picked to fresh lawns of C600. Nitrocellulose filters (Schleicher and Schuell)  
20 were then presoaked in a cell suspension of C600Hfl (a less permissive host strain) and dried. The coated nitrocellulose filters were then layered onto the phage-containing agar plates to transfer phage particles to the filters. Duplicate filters were prepared.

When the bacterial lawn had grown and plaques were apparent the filters  
25 were then employed in in situ hybridization after the method of Woo. A primary screen of 500,000 clones at 50,000 PFU/plate was performed using duplicate filters. Briefly, the filters were lifted from the plates and placed on WHATMAN 3MM filters saturated with 0.5 M NaOH and 1.5 M NaCl to lyse the bacteria and phage particles. The filters were neutralized by successive  
30 transfer to WHATMAN filters saturated with, first, 0.5 M Tris HCl, pH=7.4, with 1.5 M NaCl, and, second with 2X SSC (Maniatis et al.). The nitrocellulose

filters were then blotted dry, air dried, and baked under vacuum at 68°C for 2 hours.

The filters were prehybridized with 1X PAM containing 30% formamide. (A 1 liter solution of 2X PAM contained: 200 ml 50X Denhardt's; 500 ml 20X SSC; 100 ml 1M NaH<sub>2</sub>PO<sub>4</sub>, pH=7.0; 20 ml 100 mM PPI; 100 mM Na<sub>2</sub>HPO<sub>4</sub>; 100 ug/ml sonicated salmon sperm DNA; and, 120 mg ATP.) The prehybridization solution was removed. The hybridization was performed overnight, at 42°C, in a solution of 1 x PAM containing 30% formamide and a labeled probe set.

Two sets of probes were used to screen the duplicate filters. These probes were two sets of short oligonucleotides made to the amino-terminus of the CAP37 protein (Figure 1) as follows:

Oligo 1 (Cap37a-1), non-coding strand, amino acids 18-24, (SEQ ID NO:12): 5'-C(GT)GCCTCC(TC)TG(AG)TT(CT)TG(AG)AT-3'; and

Oligo 2 (Cap37a-2), non-coding strand, amino acids 9-15, (SEQ ID NO:13): 5'-A(GA)GAAGGG(AG)AA(CT)TG(CATG)C(GT)GGG-3'.

Bases presented in parenthesis are alternative insertions at that site.

The two sets of probes were 5' end-labelled using [ $\gamma$ -<sup>32</sup>P]ATP and T<sub>4</sub> Polynucleotide kinase (Bethesda Research Laboratories, 5'DNA Terminus Labelling System). Each set of duplicate filters were hybridized, as described above, with one of the probe sets. The filters were then washed as follows: 2 x SSC wash at 4°C (2x15 minutes) followed by a 3 M (CH<sub>3</sub>)<sub>4</sub>NCl wash at 53°C (2x15 minutes). The filters were then dried and subjected to radioautography at -20°C using intensifying screens. The duplicate filters showed one recombinant plaque that was convincingly positive with both probes.

#### Example 5

##### Analysis of the First cDNA insert in Lambda gt10

The restriction map of the cloned cDNA was determined; no internal *EcoRI* sites were detected in the sequence. The approximately 850 bp insert was removed from the  $\lambda$ gt10 vector by digestion with *EcoRI*; the corresponding DNA fragment was resolved and subsequently isolated from a polyacrylamide



gel (Maniatis et al.). This *EcoRI* fragment was then cloned into the unique *EcoRI* site of the vector pcDNAI (Figure 5; Invitrogen, San Diego, CA).

The vector pcDNAI has a Col E1 origin of replication derived from pBR322, the CMV promoter sequences and a polyadenylation signal available for expression in mammalian cells (such as COS7), and a poly-linker flanked by opposing T<sub>7</sub> and SP6 promoters providing for ease of expression of inserted DNA sequences in bacteria. The vector is also useful for DNA sequencing in that region of the poly-linker provides for the use of a universal primer homologous to the T<sub>7</sub> and SP6 promoters.

The region containing the CAP37 coding region was sequenced by standard double-strand sequencing methods (Pharmacia Sequencing Kit, Pharmacia), starting with the universal sequence primer discussed above, as well as unique synthetic oligonucleotide primers derived from the CAP37 coding sequence as they were needed. The sequence of the first cDNA clone having homology to the CAP37 coding region is shown in Figure 6.

#### Example 6

##### Characteristics of the First cDNA

The first cDNA sequence was translated into its corresponding amino acid (aa) sequence. A continuous open reading frame exits from nucleotide 176 to 856. This sequence was then aligned to the peptide fragments determined from microsequencing of the purified CAP37 protein (Figure 1). A DNA sequence encoding a protein sequence corresponding to the amino terminus of the mature CAP37 protein sequence begins at nucleotide 320. The cDNA encodes a protein in which the first amino acid of the mature protein is preceded by an in-frame open reading frame corresponding to an additional 48 amino acids. Further, the carboxy terminus of the cDNA encoded protein contained an extension, Gly Pro Ala, not present in the mature protein.

In matching the translated cDNA to the protein sequences in Figure 1 a problem was encountered in the cDNA sequence. The sequence of interest in CAP37 first cDNA is as follows (SEQ ID NO:14 and SEQ ID NO:15):

ATG CTG CTT CAG AGG TTT GTC AAC GTG ACT GTG ACC CCC GAG GAC  
 M L L Q \* R F V N V T V T P E D  
 CAG TGT CGC CCC ACC ACC GTG TGC ACC GGT GTG CTC ACC CGC CGC  
 Q C R P N N V C T G V L T R R  
 5 GGT GGC ATC TCG AAT GGG GAC GGG GGC ACC CCC CTC GTC TGC GAG  
 G G I C N G D G G T P L V C E  
 CCG CTG GCC CAC GGC  
 G L A H G.

- This sequence corresponds in part to PE-V10, an internal peptide of the CAP37 protein (amino and carboxy termini were identified, see Figure 1). A partial sequence of the PE-V10 peptide follows here (SEQ ID NO:16):

Ala Gly Thr Arg Cys Gln Val Ala Gly Trp Gly Ser Gln Arg Ser Gly  
 Gly Arg Leu Ser Arg Phe Pro \* Arg Phe Val Asn Val Thr Val Thr  
 Pro Glu Asp Gln Cys Arg.

- The 19 amino acids preceding the asterisk in the PE-V10 sequence were not represented in the first cDNA: the point of divergence in the cDNA sequence is also marked by an asterisk. Accordingly, while the first cDNA apparently coded for the majority of the CAP37 protein, it was not the correct cDNA.

- The mature C-terminal sequence of the CAP37 protein (peptide PE-T19) indicates that there is also a carboxy terminal extension present in the cDNA CAP37 protein coding sequence which is not present in the mature protein.

#### Example 7

##### 25 Isolation of a Second cDNA having Homology to Human CAP37 Protein

- A. *Amplification of a fragment spanning the region of discrepancy between the cDNA sequence and the protein sequence.*

- As a first step to clone a cDNA containing the complete CAP37 coding sequence, an attempt was made to amplify a specific DNA fragment which would span the region where the discrepancy between the cDNA sequence and the protein sequence was observed. A degenerate oligonucleotide probe corresponding to the amino acids CQVAGWG (SEQ ID NO:11) (underlined in the CAP37 peptide sequence presented in Example 6) was synthesized. The

oligonucleotide was a 20mer (256 fold degenerate, designated Intrlc), synthesized as follows (SEQ ID NO:17):

5'TG(CT)CA(AG)GT(ACTG)GC(ACTG)GG(ACTG)TGGGG 3',

where the bases in parenthesis are alternative substitutions at that site.

- 5 As a second primer for use in DNA amplification a number of 20mer primers were designed from the sequence of the non-coding strand of CAP37 first cDNA.

- Total human genomic DNA was used as template in DNA amplification reactions (Mullis; Scharf et al.) involving the above described primers. The amplification reactions were divided into two samples and each set of samples were fractionated on an agarose gel. The samples in one half of the gel (representing a complete set of amplification reactions) were transferred to nitrocellulose (Maniatis et al.). The nitrocellulose filter was hybridized (Maniatis et al.) with radiolabelled CAP37 first cDNA (Bethesda Research Laboratories Nick Translation Kit) as a probe.
- 10
- 15

- The Southern blot hybridization showed one positive band. This band was generated using primer Intrlc (above) and a non-coding strand 20 mer designated 669nc (corresponding to base pairs 652-671 of CAP37 first cDNA, Figure 6). The region of the second half of the agarose gel corresponding to the positive band was excised and the DNA extracted, phenol/chloroform extracted, and precipitated (Ausubel et al.). The band was then sequenced using the Intrlc/669nc primers (Pharmacia Sequencing Kit, Pharmacia).
- 20

The sequence of Intrlc/669nc generated band was as follows (SEQ ID NO: 18 and SEQ ID NO:19):

25

TGTAG GTT GCG GGT TGG GGG AGC CAG CAC AGT GGG GGG CGT CTC TCC CGT  
V A G W G S Q H S G G R L S R

TTT CCC AGG TTC GTC AAC GTG ACT GTG ACC CCC GAG GAC CAG TGT CGC CCC  
30 F P R F V N V T V T P E D Q C R P

AAC AAC GTG TGC ACC GGT GTG CTC  
N N V C T G V L .

B. *Second Screening of the lambda gt10/HL-60 cDNA library for a CAP37 cDNA.*

A 50mer corresponding to a region of the Intrlc/669nc sequence which was not present in the CAP37 first cDNA clone was synthesized and used as a  
5 probe to screen 200,000 clones at 50,000 PFU/plate (as in Example 4).

The sequence of the oligonucleotide probe was as follows (SEQ ID NO:20):

5' TGTCAGGTTGCGGGTTGGGGGAGCCAGCACAGTGGGGGGCGTCTCTCCCG 3'.

On an initial screen 11 positives were identified of which 5 remained  
10 positive following a secondary screen. The *EcoRI* cDNA fragment of one of these clones, designated 6a.1, was subcloned into the pcDNAI vector and sequenced using dideoxy sequencing: the 6a.1 insert subclone in pcDNAI was designated pcDNA-CAP#2. The complete DNA sequence of the 6a.1 clone is illustrated in Figure 7. The plasmid pcDNA-CAP#2 has been deposited under  
15 the terms of the Budapest Treaty with the American Type Culture Collection (12301 Parklawn Dr., Rockville MD 20852 USA) and given accession number ATCC 68340.

Example 8

Characteristics of the 6a.1 cDNA Encoded Protein

20 The 6a.1 cDNA sequence was translated into its corresponding amino acid (aa) sequence. A continuous open reading frame exists from nucleotide 4 to 756. This sequence was then aligned to the peptide fragment sequences obtained from microsequencing of the purified CAP37 protein (Example 1). The corresponding DNA coding sequence begins at nucleotide 82. All of the  
25 protein sequences determined by microsequencing of the purified CAP37 protein had corresponding protein sequences in the 6a.1 cDNA encoded protein.

The 6a.1 cDNA encodes a protein in which the first amino acid of the coding sequence of the mature protein is preceded by an in-frame open reading frame corresponding to an additional 26 amino acids: these 26 amino acids do  
30 not correspond to those seen in the first cDNA protein. The first approximately 20 amino acids of this region have a high degree of hydrophobicity (Figure 8). The length of the sequence and the degree of hydrophobicity make this

sequence an ideal candidate for a eucaryotic secretory signal sequence. The hydropathy index plot was generated using the SOAP program of PCGENE (Intelligenetics, Mountain View, CA). The SOAP program uses the method of Kyte et al to plot the hydropathicity of the protein along its sequence. The  
5 interval used for the computation was 11 amino acids.

The cDNA encoded protein apparently has a carboxy terminal extension relative to the mature CAP37 protein, i.e. Gly Pro Ala.

The portion of the open reading frame corresponding to the mature form of the protein has an estimated molecular weight of 24,276 daltons. The  
10 molecular weight previously determined for the CAP37 protein, i.e. approximately 37,000 daltons (Shafer et al., 1986), was obtained from SDS-PAGE of the purified protein. The discrepancy in molecular weight is most likely the result of post-translational modification of the CAP37 protein. For example, the CAP37 sequence has three potential N-glycosylation sites, as  
15 determined by PROSITE analysis (PCGENE Intelligenetics, Mountain View, CA) of the 6a.1 cDNA coding sequence. These potential glycosylation sites are located at asparagine residues 100, 114, and 145 of the mature sequence.

Using the method of Hopp et al. (ANTIGEN program, PCGENE Intelligenetics, Mountain View, CA), the primary antigenic determinants of the  
20 CAP37 protein sequence were determined. The three highest points of hydrophilicity are from residues 61 to 66, 5 to 10, and 150 to 156 of the mature protein sequence, with the highest average hydrophilicity value being for residues 61-66.

### 25 III. RECOMBINANT EXPRESSION OF THE CAP37 PROTEIN

Factors that are involved in successful expression of a cloned gene in a particular system include, solubility within the cell, non-toxicity to the cell, possible secretion by the expressing cell, low levels of proteolytic digestion by the cell and ease of purification in the system. Folding, disulfide bond  
30 formation, as well as post-translational modifications (glycosylation, phosphorylation, etc.) can affect expression and synthesis of proteins; these factors differ according to the host cells used for expression.

The *E. coli* plasmid system to express CAP37 was described by Smith et al. This system involves the use of a plasmid expression vector designed to direct synthesis of foreign polypeptides as fusions with the protein Sj26; Sj26 is a glutathione S-transferase protein from *Schistosoma japonicum*. Purification of the fusion protein is accomplished by affinity chromatography on immobilized glutathione. Smith et al. have described the use of expression vectors encoding a thrombin cleavage site immediately adjacent the carboxy terminus of Sj26 and the amino-terminal of the foreign protein which is to be expressed. Recovery of the foreign protein can be achieved by thrombin digestion of the purified fusion protein (Example 9-A). The thrombin digestion is followed by a final purification step to remove Sj26. High yields of several soluble proteins have been demonstrated with these plasmids.

Alternatively, the thrombin cleavage site can be replaced by another protease cleavage site such as collagenase (EC 3.4.24.3, from *Clostridium histolyticum*) by insertion of an oligonucleotide linker containing the appropriate cleavage sequence (e.g., see Example 10-B).

In addition to the above described vector there are numerous *E. coli* expression vectors known to one of ordinary skill in the art useful for the expression of CAP37 protein. If necessary an amino terminal methionine can be provided the CAP37 protein coding sequence by insertion of a Met codon 5' and in-frame with the CAP37 protein coding sequence. Also, the carboxy-terminal extension of the cDNA encoded CAP37 protein can be removed using standard oligonucleotide mutagenesis procedures.

There are several advantages to yeast expression systems. First, evidence exists that proteins produced in a yeast secretion systems exhibit correct disulfide pairing (Zsebo et al.). Second, post-translational glycosylation is efficiently carried out by yeast secretory systems (Gillis et al.; Thim et al.; Chang et al.; Hoylaerts et al.; Lemontt et al.).

The *Saccharomyces cerevisiae* pre-pro-alpha-factor leader region (encoded by the *MF $\alpha$ -1* gene) is routinely used to direct protein secretion from yeast (Brake et al., 1984). The leader region of pre-pro-alpha-factor contains a signal peptide and a pro-segment which includes a recognition sequence for a yeast

protease encoded by the *KEX2* gene: this enzyme cleaves the precursor protein on the carboxyl side of a Lys-Arg dipeptide cleavage-signal sequence. The CAP37 protein coding sequence is fused in-frame to the pre-pro-alpha-factor leader region (Example 9-B). This construct is then put under the control of a strong transcription promoter, such as the alcohol dehydrogenase I promoter or a glycolytic promoter. The CAP37 protein coding sequence is followed by a translation termination codon which is followed by transcription termination signals. Alternatively, the CAP37 protein coding sequences can be fused to a second protein coding sequence, such as Sj26 (Example 9-A) or  $\beta$ -galactosidase (Example 10-B), used to facilitate purification of the fusion protein by affinity chromatography. The insertion of protease cleavage sites to separate the components of the fusion protein, such as described above for CAP37 protein expression in *E. coli*, is also applicable to constructs used for expression in yeast.

Mammalian cells permit the expression of proteins in an environment that favors important post-translational modifications such as folding and cysteine pairing, addition of complex carbohydrate structures, and secretion of active protein.

Vectors useful for the expression of CAP37 protein in mammalian cells are shown in Figure 9. These vectors are characterized by insertion of the CAP37 protein coding sequence between a strong viral promoter and a polyadenylation signal. The vectors further contain genes conferring either Gentamicin or methotrexate resistance for use as selectable markers. The CAP37 protein coding sequence has been introduced into a Chinese hamster ovary cell line using a methotrexate resistance-encoding vector (Example 9-C). Presence of the vector DNA in transformed cells has been confirmed by Southern analysis and production of an RNA corresponding to the CAP37 protein coding sequence has been confirmed by Northern analysis.

Alternative vectors for the expression of CAP37 in mammalian cells, are those similar to those developed for the expression of human gamma-interferon, tissue plasminogen activator, clotting Factor VIII, hepatitis B virus surface antigen, protease Nexin1, and eosinophil major basic protein, will be employed (Gray et al; Wood et al.; Patzer et al.; Berman et al.; McGrogan et al, 1988

A and B). Further, the vector shown in Figure 5 contains CMV promoter sequences and a polyadenylation signal available for expression of inserted DNAs in mammalian cells (such as COS7).

The identification and use in cloning of the entire CAP37 protein coding  
5 sequenced identified by cDNA sequencing is particularly useful in mammalian cells since the putative pre-pro sequence (i.e. the first 26 amino acids of the cDNA encoded protein coding sequence) may have important effects on secretion and other protein processing events.

10

#### Example 9

##### Expression of Recombinant CAP37 Protein from the 6a.1 cDNA Coding Sequence

###### A. *Expression of CAP37 in E. coli.*

The following primers are used for DNA amplification of the CAP37  
15 coding DNA fragment from the CAP37 cDNA clone (Example 7):

5'-ATCGTTGGCGGCCGGAAGGCG-3' (SEQ ID NO:21); and,

5'-TTGGGCCCTGGCCCCGGTCGG-3' (SEQ ID NO:22).

These primers result in the amplification of the CAP37 mature protein coding  
sequence. If a 5' methionine is required for expression the first primer can be  
20 modified to :

5'-ATGATCGTTGGCGGCCGGAAGGCG-3' (SEQ ID NO:23)

to generate amplified fragments encoding a 5' methionine. Primers can also be  
designed to result in amplification of the precursor form of the CAP37 protein,  
for example:

25 5'-ATGGGGGAGGGTGGGTCC-3' (SEQ ID NO:24)

and the same second primer as above. Following confirmation by DNA  
sequencing, the amplified DNA fragment is blunt-end ligated (Maniatis et al.)  
in-frame into a plasmid expression vector (Smith et al.) designed to direct  
synthesis of foreign polypeptides as fusions with the protein Sj26; Sj26 is a  
30 glutathione S-transferase protein from *Schistosoma japonicum* (Smith et al.).  
Further, Smith et al. have described an expression vector encoding a thrombin  
cleavage site immediately adjacent the carboxy terminus of Sj26 at the site where



the amino-terminal of the foreign protein is fused. *E. coli* strain JM101 is then transformed (Maniatis et al.) with either (i) the plasmid containing the fusion protein coding sequences, or (ii) the parent plasmid without the CAP37 sequences.

- 5       The transformed cells are grown, expression of the desired proteins induced with IPTG (Smith et al.), and the cells grown a further 3-6 hours before harvest. As a control transformed cells are also grown and not induced with IPTG.

- 10       The harvested cells are then lysed (Smith et al.). A portion of each lysate is subjected to SDS-PAGE to test for expression of the fusion protein by size comparison to the native Sj26 protein and to protein molecular weight size standards. A band traveling at the molecular weight predicted for the fusion protein is expected from the lysate containing the fusion protein coding sequences, but not from lysates from cells transformed with parent vector alone or from those not induced with IPTG.

- 15       The bulk of the fusion-protein-containing lysate is treated with immobilized glutathione to purify the fusion protein (Smith et al.). This purified fusion protein is then subjected to SDS-PAGE to examine the relative purity of the preparation. The purified fusion protein is cleaved with thrombin (Boehringer-Mannheim) and the CAP37 separated from the Sj26 protein by chromatography (e.g., size exclusion chromatography followed by an ion exchange column as in Example 1).

#### B. *Expression of CAP37 in Yeast.*

- 25       For expression of CAP37 in yeast, pre-pro-alpha-factor/CAP37 gene fusions are constructed. The DNA amplified CAP37 cDNA used above for construction of *E. coli* vectors is also used for construction of yeast vectors. The expression vector contains the yeast alcohol dehydrogenase I transcription promoter and terminator (Oeda et al.). The CAP37 cDNA is blunt-end ligated, in-frame (Maniatis et al.) directly following the Lys-Arg dipeptide sequence of the pre-pro-alpha-factor leader (Kurjan et al.). This expression vector construct directs synthesis, secretion and processing of the hybrid protein in yeast.
- 30

In order to maximize protein product yield the expression vector containing the CAP37 cDNA is transformed (Ausubel et al.) into a yeast strain carrying the *pep4* mutation (Jones); such strains are defective in four major vacuolar proteases and RNase. The CAP37 protein is purified from the media by a combination of size fractionation followed by ion-exchange chromatography (Example 1). Alternatively, the yeast cells are mechanically lysed (Guarente) and the CAP37 protein isolated from the lysate in the same manner.

C. *Expression of CAP37 in Mammalian Cells.*

(i) Modification of CAP37 cDNA.

The cDNA clone encoding CAP37 was modified to be bounded by a *HindIII* restriction site at the 5' end of the sequence and a *XbaI* site at the 3' end as follows. Two primers for use in DNA amplification reactions were designed to be complementary to the ends of the CAP37 cDNA and contain the desired restriction sites. The sequence of the two primers used to prepare the DNA amplification product were: (SEQ ID NO:25 and SEQ ID NO:26)

5': 5'-CCGGAATTCCAAGCTTCCACCATGACCCGGCTGACAGTCCTGG-3'  
HindIII

3': 5'-CCGGATCCTCTAGACCCTAGGCTGGCCCCGGTCCCGG-3'.  
XbaI

The DNA was amplified as per the manufacturers instructions (Cetus-Perkin Elmer, Norwalk CT). The resulting 5' end contained a *HindIII* site followed by the consensus mammalian initiator sequence CCACCATG.

(ii) Construction of Vectors.

The above modified CAP37 cDNA was inserted into a series of expression vectors having the following properties:

1. Unique *HindIII* and *XbaI* cloning sites situated between a strong viral promoter (either CMV, SV40, or RSV) and a polyadenylation signal derived from SV40).

2. A selectable marker linked to the vector conferring either Gentamicin resistance or methotrexate resistance.

The vectors are shown in Figure 9.

In Figure 9, plasmid vector sequences derived from pUC18 are denoted by the thin line. The promoter preceding the CAP37 cDNA insert was joined to the pUC polylinker at the *EcoRI* site. The cytomegalovirus (CMV) promoter cassette (pCXSD-CAP37 and pCXRD-CAP37) was a 637 bp fragment which contains the promoter and enhancer of the immediate early gene 1 (IE1) of CMV (Seed). The promoter cassette was modified to be bounded by an *EcoRI* restriction site at the 5' end of the cassette and *HindIII* and *BglII* sites at the 3' end of the cassette. The SV40 sequences flanking the 3' end of the CAP37 cDNA insert was composed of two elements from the SV40 early region. A 620 bp *Sau3A* fragment spanning the T antigen splice signal was joined to the 350 bp *BclI-BamHI* fragment of SV40 which spanned the polyadenylation signal of the SV40 early gene (Seed). The dihydrofolate reductase (DHFR) cassette was derived from a murine cDNA encoding DHFR and modified to contain a *BglII* site preceding the translational start site of the clone and ending at a *Sall* restriction site situated adjacent to the *BglII* restriction site of DHFR (Simonsen et al.). The SV40 E promoter cassette, at the 5' end of the DHFR insert in pCXSD-CAP37, was a 540 bp fragment which spanned the SV40 origin of replication, early, and late promoters, and is bounded by an *EcoRI* (Simonsen et al.). This SV40 promoter cassette can also be used for expression of the CAP37 cDNA (e.g., pSXRD-CAP37). The RSV promoter cassette, at the 5' end of DHFR in pCXRD-CAP37 and pSXRD-CAP37, was derived from the Rous Sarcoma Virus and spans the LTR, ending at a point 90 base pairs downstream of the transcriptional start site (Seed). The HBV 3' end of the each vector was a 585 bp *BamHI-BglII* fragment which spanned the HBV surface antigen polyadenylation signal (Simonsen et al.).

(iii) Derivation of Transformed Cell Lines.

Host cell lines which can be transformed using the above described vectors include human, mouse, and hamster. The preferred host cell line is a Chinese Hamster Ovary cell line (CHO) which has been rendered incapable of producing the enzyme dihydrofolate reductase (Urlaub et al.): the expression of CAP37 is not limited to this line. Typically, use of vectors containing a gene encoding dihydrofolate reductase (DHFR) has allowed for the efficient selection

of stable cell lines expressing the transfected plasmid. In addition, such cell lines are capable of being selected with the folate analogue methotrexate, resulting in the emergence of cells having amplified copies of the DHFR cDNA and the co-transfected sequences (Simonsen et al.; McIvor et al.; McGrogan et al., 1988 A).

Plasmid DNA containing the CAP37 protein encoding cDNA and the DHFR-encoding gene was transfected into CHO cells using the cationic liposome method (DOTMA).  $2 \times 10^5$  cells were passaged into 5-25 flasks 48 hours prior to the transfection and allowed to grow in non-selective media. Ten ug of plasmid DNA was diluted to 50 ul with sterile distilled water and then added to 25 ug of DOTMA (Lipofectin, Bethesda Research labs) in a volume of 50 ul. The DNA was mixed and allowed to stand 30 minutes at room temperature. Immediately prior to the addition of the DNA to the cells, the T-flasks were washed three times with serum-free media. Three milliliters of serum-free media was added to each T-flask, after which the DOTMA-DNA mixture was added to the cells. The flasks were swirled and returned to the incubator for 4 hours. Three milliliters of fresh media with 20% serum was then added to each flask of cells and the cells allowed to incubate for 48-72 hours at which time the cells were removed by trypsinization, split into 10 cm dishes, and suspended in selective media containing methotrexate.

The cells were returned to the incubator and allowed to grow with twice-weekly changes of media. After 2-3 weeks, colonies become apparent. Cloning cylinders were used to isolate and subclone colonies arising from an individual transfected cell.

Both bulk populations and subclones were expanded for protein assay by Western blot assays (Ausubel et al.). Cell lines expressing CAP37 antigen were selected for amplified CAP37 expression by growing the cells in stepwise increasing levels of methotrexate (MTX). Cell lines resistant to  $1 \mu\text{M}$  MTX were subcloned and characterized by Northern and Southern analysis (Maniatis et al.), doubling time, expression levels and stability of expression.

In addition to the above bacterial, yeast, and mammalian systems there are numerous expression systems, well known to one of ordinary skill in the art,

available suited to the expression of CAP37 (eg., Kingsman et al.; Brake, 1989; Revel et al.; Moriarty et al.; Kopchick et al.).

For all of the above expression systems antibodies generated to the CAP37 protein, or portions thereof, (Examples 1 and 15) can be used to follow and to quantitate the CAP37 produced; the antibodies are particularly useful for following the purification of CAP37 as, for example, described above in the *E. coli* system.

#### IV. BIOACTIVE PEPTIDE FRAGMENTS OF THE CAP37 PROTEIN

A bioactive portion of the CAP37 protein is defined as a peptide fragment of at least about 5 consecutive amino acids derived from the CAP37 protein coding sequence (Figure 7) or the mature CAP37 protein (SEQ ID NO:9) which has chemotactic or lipopolysaccharide-binding or antibacterial properties (Example 11-14). As used herein, the term "peptide derived from CAP37" refers to a peptide that contains a bioactive portion of the CAP37 protein. Thus, a peptide derived from CAP37 may be a peptide that consists of at least 5 consecutive amino acids from the CAP37 protein coding sequence or may be a peptide that contains at least 5 consecutive amino acids from the CAP37 protein coding sequence in its sequence. Examples of the latter include sequences such as SEQ ID NO:29 (Example 12), sequences that contain a CAP37 bioactive portion attached to sequences designed to provide for some additional property, such as solubility, and CAP37 sequences in which one or more amino acids have been substituted with another amino acid to provide for some additional property, such as to remove/add amino acids capable of disulfide bonding, to increase its bio-longevity or to alter its cytotoxicity. Examples of peptides derived from CAP37 include the sequences found in SEQ ID NO:1 to SEQ ID NO:9 and SEQ ID NO:29. In any case, the peptide must possess the bioactive property, such as monocyte chemotactic, LPS-binding or antibacterial.

One method of identifying bioactive fragments is described in Examples 10 and 11. In this method, the CAP37 protein coding sequence is fragmented by digestion with DNase I (Example 10-A). The CAP37 protein coding

sequence could also be fragmented using specific restriction endonucleases, such as *HaeIII* which has 19 cut sites in the coding sequence. These fragments are then ligated into a vector which allows identification of in-frame fusions by a simple plate assay (Example 10-B). The presence of CAP37 protein coding  
5 DNA sequences can be verified in the clones utilizing colony hybridization. The in-frame fusions represent candidate CAP37 peptides which can be assayed for their chemotactic, antibiotic and lipopolysaccharide binding properties as described in Example 11.

Glycosylation and other post-translational modifications may not be  
10 required to detect these activities, thus expression of these peptides in *E. coli* is the method of choice. However, the fusions of the bioactive peptides to  $\beta$ -galactosidase can also be expressed in yeast or mammalian cells essentially as described above and in Example 9.

Another method of identifying bioactive fragments of CAP37 is described  
15 in Examples 12, 13 and 14. Because the amino acid sequence of the mature CAP37 protein is given above, it is possible to synthesize, using standard peptide synthesis techniques, peptide fragments chosen to be homologous to regions of the CAP37 protein and to modify these fragments by inclusion, deletion or modification of particular amino acids residues in the derived sequences. Thus,  
20 creation of an extremely large number of peptides derived from CAP37 is possible. However, selection of the particular sequences that provide bioactive activity is not straight-forward.

This invention discloses peptides derived from the mature CAP37 protein having chemotactic activity for monocytes, peptides derived from the mature  
25 CAP37 protein having antibacterial or bactericidal activity and peptides derived from the mature CAP37 protein having LPS-binding activity. Interestingly, the regions of the mature CAP37 protein that produce chemotactic fragments are different from those that produce either antibacterial or LPS-binding fragments. In particular, peptides derived from the 115th to 122nd amino acid region of  
30 CAP37, the 133rd to 141st amino acid region of CAP37 and the 45th to 51st amino acid region of CAP37 possess chemotactic activity. Preferred chemotactic peptides are those amino acid sequences that possess monocyte chemotactic

activity and comprise those sequences defined in the Sequence Listing by SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5, most preferably those that consist of those sequences defined in the Sequence Listing by SEQ ID NO:2, SEQ ID NO:4 AND SEQ ID NO:6. Further, peptides derived from the 23rd-42nd amino acid region of the mature CAP37 protein possess antibacterial activity and/or LPS-binding activity. Preferred antibacterial and/or LPS-binding peptides are those that possess either antibacterial and/or LPS-binding activity and comprise those amino acid sequences defined in the Sequence Listing by SEQ ID NO:7, most preferably the peptide consisting of SEQ ID NO:8. Surprisingly, these fragments appear to possess antibacterial activity against many bacteria (both gram negative and gram positive) that the purified mature protein is not active against as well as possessing enhanced activity against bacteria such as *Salmonella typhimurium* and *Escherichia coli*. These peptide fragments have further advantages over the mature CAP37 protein: their small size permits essentially unlimited production of these compounds (the preferred size is approximately 2500 to 3000 daltons) and their therapeutic use is not limited due to the potential hazards, such as being infectious, associated with using human blood products.

20

### Example 10

#### Preparing Cloned Peptide Fragments

##### A. DNA Fragment Digestion.

The amplified 6a.1 CAP37 cDNA described above in Example 9 is modified by treatment with *EcoRI* methylase under standard conditions (Promega). The DNA is phenol/chloroform extracted and ethanol precipitated. The modified DNA is suspended in a standard digest buffer (0.5M Tris HCl, pH 7.5; 1 mg/ml BSA; 10mM MnCl<sub>2</sub>) to a concentration of about 1 mg/ml and digested with DNase I at room temperature for various times (1-5 minutes). These reaction conditions were determined from a prior calibration study, in which the incubation time required to produce predominantly 100-200 basepair fragments was determined. The material was extracted with phenol/chloroform before ethanol precipitation.

The fragments in the digest mixture were blunt-ended using DNA Polymerase I (Maniatis et al.) and ligated with the *EcoRI* linkers. The fragments were then digested with *EcoRI* under standard conditions (Promega). The resultant fragments were analyzed by electrophoresis (5-10V/cm) on 1.2% agarose gels, using PhiX174/HaeIII and lambda/HindIII size markers. The 50-200 bp fraction was eluted onto NA45 strips (Schleicher and Schuell), which were then placed into 1.5 ml microtubes with eluting solution (1 M NaCl, 50 mM arginine, pH 9.0), and incubated at 67°C for 30-60 minutes. The eluted DNA was phenol/chloroform extracted and then precipitated with two volumes of ethanol. The pellet was resuspended in 20 µl TE buffer (0.01 M Tris HCl, pH 7.5, 0.001 M EDTA).

#### B. Cloning the Digest Fragments.

The pUC7 plasmid (Messing) is modified to encode a collagenase (EC 3.4.24.3, from *Clostridium histolyticum*, available from Boehringer Mannheim) cleavage site using the following linker (SEQ ID NO:27):

```

20  GAT CCG CCT GCA GGC CCT GTA AGC TTG AGG
      GC GGA CGT CCG GGA CAT TCG AAC TCC AGC T
      BamHI                      HindIII      SalI.

```

Insertion of the above linker between the *BamHI* and *SalI* sites of the pUC7 plasmid results in the introduction of a collagenase cleavage site (Pro Ala | Gly Pro Val), and a diagnostic *HindIII* site into the plasmid (designated pUC7-C). Further, the linker maintains a contiguous open reading frame into the β-galactosidase protein coding sequence. The phosphorylated oligonucleotides are synthesized by standard methods. The oligonucleotides are then mixed in an equimolar amount, heated and renatured by cooling to form the above duplex linker.

The pUC7-C plasmid is digested with *EcoRI* and treated with calf-intestinal phosphatase (Promega). The digest fragments from Part A were introduced into the *EcoRI* site by mixing 0.5-1.0 µg *EcoRI*-cleaved pUC7-C, 0.3-3 µl of the above sized fragments, 0.5 µl 10X ligation buffer (Maniatis et al.), 0.5



0.5  $\mu$ l DNA ligase (200 units), and distilled water to 5  $\mu$ l. The mixture was incubated overnight at 14°C.

The ligation mixtures are then transformed into *E. coli* strain JM101 and plated on YT media (Gibco) containing ampicillin (100  $\mu$ g/ml) at a density of 300-500 colonies per plate. The plates are replica-plated to X-gal indicator plates (Miller), YT+amp, and to nitrocellulose filters (Grunstein et al.). Blue colonies are scored on the X-gal indicator plates and indicate possible in-frame fusions of an inserted DNA fragment (Part A) to the *lacZ* gene contained in the vector. The nitrocellulose filters are screened as follows. The amplified 6a.1 cDNA is digested with the restriction enzyme *HaeIII* under standard reaction conditions (New England Biolabs): the 6a.1 cDNA has 19 *HaeIII* sites. The resulting DNA fragments are then phenol/chloroform extracted and precipitated with ethanol. The DNA is resuspended and radioactively labelled by nick-translation (Bethesda Research Laboratories). The nitrocellulose filters are hybridized with the labelled 6a.1 cDNA as previously described (Grunstein et al.). The filters are then washed and subjected to autoradiography.

pUC7-C vectors which contain inserts from the 6a.1 cDNA will test positive by this screen. These positive colonies are further screened by comparison to the colonies on X-gal plates. Bacterial colonies which test positive for the presence of a fragment of the 6a.1 cDNA and are blue are candidates for in-frame fusions of fragments of the CAP37 coding sequence to  $\beta$ -galactosidase.

These candidates are picked to master plates. The candidates are inoculated into YT+ampicillin (Maniatis et al.) and grown to mid-log phase. The cultures are combined in groups of 5. The combined cells are pelleted by centrifugation and suspended in lysis buffer (10 mM Tris, pH=7.4, containing 2% Triton X-100™, with 1% aprotinin added just before use). The resuspended cells are frozen in liquid nitrogen, then thawed, resulting in substantially complete cell lysis. The lysate is treated with DNaseI to digest bacterial DNA, as evidence by a gradual loss of viscosity in the lysate. Non-solubilized material is removed by centrifugation.

SEPHAROSE 4B beads conjugated with anti-beta galactosidase are purchased from Promega. The beads are packed in a column and washed successively with phosphate-buffered saline with 0.02% sodium azide and 10 ml TX buffer (10 mM Tris buffer, pH 7.4, 1% aprotinin). The clarified lysate  
5 material is loaded on the SEPHAROSE column, the ends of the column are closed, and the column is placed on a rotary shaker for 2 hrs. at room temperature and 16 hours at 4°C. After the column settles, it is washed with TX buffer. The CAP37 protein fragments are released by collagenase cleavage (Scholtissek et al.; Ullmann). The eluent is then concentrated by ultrafiltration.

10

#### Example 11

##### Characterization of CAP37 Protein Fragments

##### A. *Identification of CAP37 fragments having chemotactic properties.*

The eluents generated in Example 10 are evaluated for their effects on  
15 human monocyte chemotaxis by the method of Cates et al. Briefly, one filter at a time is placed in the Boyden chamber (Neuroprobe, Bethesda MD). The eluent to be analyzed for its chemotactic activity is placed in the lower chamber. A cell suspension of monocytes is placed in the upper compartment. The filled chambers are then briefly spun in a Sorvall centrifuge, covered to prevent  
20 evaporation, and incubated at 37°C for approximately 120 minutes.

The filters are then removed from the Boyden chamber, stained, and fixed. The number of monocytes adhering to the chemoattractant side of the filter represent a fraction of the cells that have migrated through the filter in response to the chemoattractant. The number of monocytes in a 5 X 5 mm grid  
25 is counted for 10 randomly selected high-power fields (10 X ocular, 45 X objective) for each filter and an average cell number per grid value determined.

The number of cells migrating in response to buffered HBSS (Hank's Balanced Salt Solution; Gibco, Grand Island NY) alone is also determined and is subtracted from the average number of cells per grid migrating in response to  
30 the potential chemoattractant. The number of cells migrating in response to the CAP37 protein, also determined as just described, is used as a positive control to

represent 100% chemotactic activity. The eluents are evaluated as the percent of the control chemotactic activity as follows:

$$100 \times \frac{\text{corrected average number of cells per grid eluent}}{\text{corrected average number of cells per grid CAP37}}$$

An average of three filters per eluent are tested in addition to the above controls. When a pool of eluent is identified as containing a chemotactic agent, the clones comprising the pool are individually tested in the above manner to identify the clone(s) responsible for the chemoattractant property.

10

B. *Identification of CAP37 fragments having lipopolysaccharide-binding properties and/or antibiotic activity.*

Pooled eluent is prepared as described in Example 10-A. The eluents are tested for lipopolysaccharide neutralizing capacity using the Limulus Amebocyte Lysate (LAL) Assay as previously described by Warren et al. Briefly, the pooled eluent sample is diluted 1:1 in normal saline (USP Abbott Laboratories, Chicago IL) and added to serial two-fold dilutions, made in normal saline, of *E. coli* lipopolysaccharide (Whittaker Bioproducts, Inc., Walkersville, MD) contained in wells of a 96 well microtiter plate (Flow Laboratories, McLean VA). The mixtures are incubated for approximately 3 hours at 37°C followed by the addition of reconstituted LAL (Whittaker Bioproducts, Inc., Walkersville, MD). The reactions are incubated for 1 hour at 37°C and then read using a microplate reader (Flow Laboratories, McLean VA) set at 380 nm.

To evaluate LPS neutralization capacity of the eluent, the results of the above assays are plotted and the LPS concentration needed to produce 50% of the maximal increase in O.D.<sub>380</sub>, i.e. the maximum O.D. produced in the presence of excess LPS, is determined by interpolation. This value is called the 50% limulus gelatin response (LR<sub>50</sub>; Warren et al.).

Each microtiter plate has the following two controls: (i) a saline control, that is, no potential neutralizing agent; and, (ii) a dilution of purified CAP37 protein as a neutralizing agent control. LR<sub>50</sub> values elevated above the saline control indicate potential LPS neutralizing peptide fragments of the CAP37

protein. When a pool of eluent is identified as containing a potential LPS neutralizing agent, the clones comprising the pool are individually tested in the above manner to identify the clone(s) responsible for the LPS neutralizing property.

- 5 Pooled eluent can also be tested for antibiotic activity using, for instance the assay for determining bactericidal activity as outlined in Example 13. When a pool of eluent is identified as containing a potential antibiotic CAP37 fragment, the clones comprising the pool can be individually tested in the same manner to identify the clone(s) responsible for the antibiotic property.

10

C. *Characterization of Identified Clones.*

- The CAP37-encoding inserts of clones identified as of interest for either chemotactic or LPS binding properties are sequenced using dideoxynucleotide double-strand sequencing (Pharmacia Sequencing Kit, Pharmacia). Universal  
15 primers, corresponding to vector sequences which flank the inserts, are employed in the sequencing reactions. The insert sequences are then aligned with the complete CAP37 sequence to identify the locations of these regions of interest in the corresponding CAP37 protein sequence.

20

Example 12

Identification of Synthesized Peptide  
Fragments having Chemotactic Activity

- The amino acid sequence of CAP37 was compared to that of elastase and cathepsin G, two serine proteases with which CAP37 has close homology.  
25 Because neither elastase nor cathepsin G exhibit monocyte chemotaxis, stretches of the CAP37 molecule which were the least homologous to either cathepsin G or elastase were selected as fragment likely to have monocyte chemotactic activity. Three such fragments:

Peptide 1, F-Q-S-Q-N-P-G-V-S-T-V

30

(Amino acids 43 - 53; SEQ ID NO:6);

Peptide 2, S-I-S-S-M-S-E-N-G

(Amino acids 72 - 80; SEQ ID NO:28); and

Peptide 3, S-Q-H-S-G-G-R-L-S-R-F-P-R-F

(A peptide derived from CAP37 (amino acids 130 - 143) in which 132aa has been changed from Arg to His; SEQ ID NO:29) were identified and synthesized using standard peptide synthesis techniques.

- 5        The three peptides were tested for chemotactic activity towards monocytes using the modified Boyden Chamber technique described in Example 2. The monocyte chemotactic activity of each peptide fragment at concentrations ranging from  $10^{-7}$  to  $10^{-13}$ M was compared with Geys buffer (negative control), FMLP  $10^{-8}$ M (positive control) and purified CAP37  $10^{-9}$ M
- 10       (positive control). Peptides 1 and 3 showed chemotactic activity for monocytes while peptide 2 did not. The effect of peptide 1 on monocyte chemotaxis is illustrated in Table 2 while the effect of peptide 3 on monocyte chemotaxis is illustrated in Table 3. The results with both peptides 1 and 3 show that significant chemotaxis occurs at  $10^{-10}$ M concentration.

15

TABLE 2: Effect of Peptide #1 on Monocyte Chemotaxis

Chemoattractant Conc.	Distance migrated in $\mu$ m
20 $10^{-7}$ M peptide #1	57.2
$10^{-8}$ M peptide #1	51.5
$10^{-9}$ M peptide #1	57.7
$10^{-10}$ M peptide #1	63.5
$10^{-11}$ M peptide #1	51.3
25 $10^{-12}$ M peptide #1	50.2
$10^{-8}$ M FMLP	86.2
$10^{-9}$ M CAP 37	78.4
30        Geys buffer	45.8

TABLE 3: Effect of Peptide #3 on Monocyte Chemotaxis

	Chemoattractant Conc.	Distance migrated in $\mu\text{m}$
5	$10^{-8}\text{M}$ peptide #3	46.5
	$10^{-9}\text{M}$ peptide #3	52.0
	$10^{-10}\text{M}$ peptide #3	66.6
	$10^{-11}\text{M}$ peptide #3	52.8
	$10^{-12}\text{M}$ peptide #3	50.5
	$10^{-13}\text{M}$ peptide #3	50.2
10	$10^{-8}\text{M}$ FMLP	91.4
	$10^{-9}\text{M}$ CAP 37	73.6
15	Geys buffer	43.9

To further ascertain the identity of peptides derived from CAP37 that have monocyte chemotactic activity, the following peptide fragments of CAP37 were synthesized using standard peptide synthesis techniques: 38-53aa; 95-122aa; 102-122aa; 113-122aa; and 130-146aa; in which the numbers refer to the amino acid positions in the mature CAP37 protein (SEQ ID NO:9). Each of these peptide fragments were tested as above for monocyte chemotactic activity. The peptide derived from CAP37 having aa102-122 exhibited two-thirds the monocyte chemotactic activity of the mature CAP37 protein. Further, lengthening this peptide to 95-122aa virtually destroyed the chemotactic effect whereas shortening the peptide to 113-122aa reduced the chemotactic activity, although this fragment still possessed reasonable activity. The effect of 95-122aa, 102-122aa, and 113-122aa at various concentration on monocyte chemotaxis is shown in Figure 11.

### Example 13

#### Identification of Synthesized Peptide Fragments having Antibiotic Activity

To identify peptides derived from the mature CAP37 protein that have antibiotic activity, various peptide fragments were synthesized using standard peptide synthesis techniques. These peptides were tested, using the following

procedure, to determine the extent, if any, of bactericidal activity for each fragment.

An overnight culture of *Salmonella typhimurium* (or other microorganism of interest, if desired) is set up by inoculating one colony in 5ml of LB Broth (LB Broth consists of 10 g BACTO tryptone (DIFCO), 5 g BACTO yeast (DIFCO) and 5 g NaCl made up to 1 L with endotoxin free water; add 15 g of BACTO agar (DIFCO) to this broth to make LB agar (autoclave). The culture is incubated at 37°C with rotation. 100 µl of this overnight culture is then transferred to 5ml of fresh LB Broth and incubated at 37°C with rotation for 2 hours. Four ml of this log phase culture is then transferred to a sterile cuvette and the optical density is read at 520 nm. Dilutions of the microorganism are then made in tryptone saline (5 g BACTO tryptone (DIFCO) and 5 g NaCl made up to 1 L with endotoxin free water, pH 5.5) to give a final concentration of  $5 \times 10^3$  organisms/ml (an O.D. reading of 0.25 at 520 nm is equivalent to  $1 \times 10^8$  organisms/ml). The microorganisms are placed at 4°C until ready to be used.

The stock solutions of peptides are stored at -20°C at concentrations of 1 mg/ml of endotoxin-free water. The peptide is diluted out in tryptone saline to the desired concentration. 100 µl of the peptide is added to each well of the microtitre plate (Corning) and then 100 µl of the bacterial suspension (well vortexed) is added. Each assay point is set up in triplicate. 100 µl of a control, consisting of bacteria and tryptone saline (T=0) in the absence of peptide is plated out on LB agar plates. The microtitre plate is then incubated at 37°C for 1 hour. At the end of the incubation time, 100 µl of each sample is plated out on LB agar plates. The T = 60 control (consisting of bacteria and tryptone saline in the absence of peptide) is plated out last. The plates are incubated overnight, and the number of colony forming units (CFU) are determined.

The % killed is determined as follows:

$$\% \text{ killed} = 100 \times \frac{\text{CFU in absence of peptide} - \text{CFU in presence of peptide}}{\text{CFU in absence of peptide}}$$

Fig. 12 shows the bactericidal effect of peptides derived from CAP37 1-25aa; 20-44aa; 38-53aa; 43-53aa; 72-80aa; 95-122aa; 102-122aa; 113-122aa; 130-

146aa; 140-165aa and 198-201aa on *Salmonella typhimurium* SH9178 at concentration ranging from 12.5 µg/ml to 200 µg/ml. As can be seen, CAP37 fragment 20-44aa (SEQ ID NO:8) is the most potent antibiotic of these peptides; 20-44aa is an extremely potent antibiotic peptide.

5 To determine the minimum or critical number of residues required for antibiotic activity in the 20-44aa region, peptides of slightly greater or lesser length were synthesized also. Figure 13 shows the bactericidal effect of peptides 1-44aa; 1-25aa; 1-5aa; 6-25aa; 20-29aa; 20-44aa; 29-44aa; 24-42aa; 24-44aa; 26-42aa; and 27-41aa on *Salmonella typhimurium* SH9178. Strongest activity was  
10 obtained with peptide 20-44aa (SEQ ID NO:8). Peptide 1-44aa is also active but not to the same extent as peptide 20-44aa. In contrast to cathepsin G in which amino acids 1-5 of that sequence are mildly bactericidal, the first 5 amino acids of CAP37 (1-5aa) is not active at the concentrations tested.

From this data, it appears that the two cysteines at residues 26 and 42 are  
15 important for activity of the peptide. The peptide 27-41aa, which lacked both cysteines, possessed no bactericidal activity. Peptide 26-42aa has minimal activity. However, this peptide, along with 24-44aa and 24-42aa, are not very soluble. Peptides 20-29 and 29-44 have no activity and peptide 1-25 is not active either. The cysteines at residues 26 and 42 may help the molecule to become  
20 cyclic, and thus enhance the peptide's ability to insert into the bacterial membrane, because of a disulfide bridge between the two cysteines. To test this theory, peptide 20-44ACM was synthesized such that the cysteines at 26 and 42 have the side chain ACM added to them to stop disulfide bridge formation and, hence, any cyclic compound formation. Thus, 20-44ACM is basically linear or  
25 stretched out. As can be seen in Figure 13, no or very reduced antibiotic activity was obtained with this peptide, indicated that some cyclic native is required to allow insertion in the bacterial membrane. Thus, it appears that at least the amino acid sequence 23-42aa (SEQ ID NO:7) is necessary for heightened antibiotic activity.

30 Antibiotic peptide 20-44aa derived from CAP37 (SEQ ID NO:8) is active against a wide assortment of bacteria, including both gram negative and positive bacteria. Figure 14 shows the bactericidal effect of CAP37 peptide 20-44 on



*Escherichia coli* (gram negative), *Staphylococcus aureus* (gram positive),  
*Enterococcus faecalis* (gram positive), *Streptococcus pyogenes* (gram positive),  
*Listeria monocytogenes* (gram positive), *Pseudomonas aeruginosa* (gram negative),  
*Proteus mirabilis* (gram negative), *Morganella morganii*, *Salmonella typhimurium*  
5 *LT2* (wild type, gram negative), *Salmonella typhimurium* SH9178 (Rb chemotype,  
gram negative), *Salmonella typhimurium* (SH7518, Re chemotype, gram  
negative). These results indicate that CAP37 peptide 20-44 is most active  
against *Pseudomonas*, *E. faecalis*, *E. coli* and *Salmonella typhimurium* LT2,  
SH9178 and SH7518.

10 Table 4 shows a comparison of the bactericidal activity of peptide 20-44aa  
(SEQ ID NO:8) against the activity of crude granule extract (CGE) from normal  
human neutrophils and the activity of CAP37 itself (including values for some  
organisms obtained from the Shafer (1986) paper). Surprisingly, peptide 20-  
44aa is more active against certain bacteria (i.e., *Salmonella* LT2, *E. coli*,  
15 *Pseudomonas*, *E. faecalis*, and *Pr. mirabilis* Re45) than either the CGE or the  
CAP37. CAP37 was originally shown to be active mainly against *Salmonella*  
*typhimurium* and *Escherichia coli*. The peptide 20-44aa derived from the mature  
CAP37 protein, in addition to being very active against these two gram negative  
bacteria, appears to be active against many other bacteria (including some gram  
20 positives) that the purified protein is not active against. Thus, the activity of the  
peptide appears to be much more potent than the whole protein.

A comparison of the bactericidal activity of the 20-44aa protein derived  
from CAP37 to elastase peptide 20-44aa and cathepsin G peptide 20-47aa was  
undertaken, using the bactericidal assay discussed above, to ascertain if these  
25 other similar proteins had similar active sites. The results of this comparison are  
given in Figure 15 and indicate that CAP37's peptide fragment, 20-44aa, is  
extremely active while cathepsin G, 20-27aa is not bactericidal and elastase 20-  
44aa is active but only at the highest concentration. Results at 100 and 125  $\mu$ M

TABLE 4

	% survival with peptide 20-44		No. expts	% survival with CGE 20 ug/ml	No. expts	% survival with CAP 37
	75 uM	50 uM				
<i>Salmonella</i> LT2	1.7	28.5	1	45.8	1	43 (Shafer, 1986)
<i>Salmonella</i> SH9178	3.5	36.9	3	4.5	1	Not done
<i>Salmonella</i> SH7426	31.9	62.5	2	17.8	1	64.3
<i>Salmonella</i> SH7518	0	0.6	2	1	1	10.9
<i>E. coli</i>	0	24.6	2	31.2	3	4 (Shafer, 1986)
<i>Ps. aeruginosa</i>	0	0	1	28.1	1	36 (Shafer, 1986)
<i>E. faecalis</i>	0	16.1	3	49.8	2	Not done
<i>P. mirabilis</i> Re45	29	26.8	1	59.3	1	100 (Shafer, 1986)
<i>L. monocytogenes</i>	64.6	65.8	1	40.2	1	Not done
<i>S. aureus</i> 502A	27.5	58.7	1	Not done		Not done
<i>Strep. pyogenes</i>	78	93.4	1	Not done		Not done

indicate that CAP37's fragment, peptide 20-44aa, is the very much more bactericidal.

#### Example 14

5

##### Identification of Synthesized Peptide Fragments having Lipopolysaccharide Binding Activity

To identify those peptides derived from CAP37 having bacterial LPS-binding activity, the peptide fragments having bactericidal activity were tested to ascertain whether LPS or Lipid A inhibited that activity. Figure 16 shows the inhibition of the bactericidal effect of peptide 20-44aa (SEQ ID NO:8) on *Salmonella typhimurium* SH9178 by wild type LPS and Lipid A. The peptide at 200 µg/ml was incubated with the indicated amounts of LPS and Lipid A and then incorporated in the bactericidal assay (Example 13). The percent killed is indicated and shows that wild type LPS, but more particularly Lipid A, can inhibit the bactericidal effect of peptide 20-44aa on SH9178. This inhibition strongly suggests that LPS binds to the peptide, interfering with its antimicrobial activity.

As discussed in Example 11, peptides can be screened for lipopolysaccharide neutralizing capacity using the LAL assay also. The CAP37 peptide was diluted to the desired concentrations (from 125 ng/ml to 4000 ng/ml) in geys buffered saline pH 7 (GIBCO). To this is added the wild type LPS (RIBI IMMUNOCHEM) or Re LPS from *Salmonella* (David Morrison, Kansas Medical Center) so that the final concentration is 0.1, 0.5, and 1.0 ng/ml LPS. The tubes were incubated at 37°C for between 30 to 60 minutes and then assayed in the chromogenic LAL assay.

Figure 17 shows the results of neutralization of LPS activity by peptide 20-44aa (SEQ ID NO:8) by the LAL assay. The absorbance at 405 nm in Figure 17A indicates that the 20-44aa peptide derived from CAP37 can bind to wild type LPS, neutralizing its effect to a certain extent. However, as shown in Figure 17B, the neutralizing effect when ReLPS is used is more dramatic. This result indicates that peptide 20-44aa is more likely to bind the rough strains of LPS and Lipid A more than smooth LPS.

### V. Anti-CAP37 Antibodies

In another aspect, the invention includes an antibody which is specific against CAP37 protein or bioactive peptides derived from CAP37, or specific against CAP37 protein/peptide fusion proteins (Examples 9-14). To prepare antibodies, a host animal, such as a rabbit, is immunized with the purified CAP37 protein/peptide antigen. The host serum or plasma is collected following an appropriate time interval, and this serum is tested for antibodies specific against the CAP37 protein antigen. Example 15 describes the production of rabbit serum antibodies which are specific against CAP37 protein, a peptide derived from CAP37 or protein/peptide fusion proteins.

The gamma globulin fraction or the IgG antibodies of immunized animals can be obtained, for example, by use of saturated ammonium sulfate or DEAE SEPHADEX, or other techniques known to those skilled in the art for producing polyclonal antibodies.

Alternatively, the purified antigen may be used for producing monoclonal antibodies. Here the spleen or lymphocytes from an immunized animal are removed and immortalized or used to prepare hybridomas by methods known to those skilled in the art.

Antibodies secreted by the immortalized cells are screened to determine the clones that secrete antibodies of the desired specificity (Example 15), for example, using the Western blot method (Ausubel et al.).

#### Example 15

##### Preparation of Anti-CAP37 Antibodies

The fusion protein containing the full length CAP37 protein and glutathione S-transferase (Example 9-A) is isolated from lysed bacteria. Transformed bacteria are streaked for single colonies, grown at 37°C overnight or until colonies are apparent. Individual colonies are inoculated into 1 ml of selection media and grown overnight. Saturated overnight bacterial culture are used to inoculate cultures, which are incubated with aeration to an O.D. of about 0.5-0.6. The cells are pelleted by centrifugation, and resuspended in lysis buffer (62 mM Tris, pH 7.5 containing 5% mercaptoethanol, 2.4 % SDS and

10% glycerol). The lysate is treated with DNaseI to digest bacterial DNA, as evidence by a gradual loss of viscosity in the lysate. Non-solubilized material was removed by centrifugation. The fusion protein is isolated from the bacterial lysate by treatment with immobilized-glutathione (Smith et al.).

- 5 For the isolation of CAP37/ $\beta$ -galactosidase fusion proteins (Examples 10 and 11), the cells are pelleted by centrifugation and suspended in lysis buffer (10 mM Tris, pH 7.4 containing 2% TRITON X-100 and 1% aprotinin added just before use). The resuspended cells are frozen in liquid nitrogen, then thawed, resulting in substantially complete cell lysis. The lysates are treated with DNaseI  
10 to digest bacterial DNA, as evidence by a gradual loss of viscosity in the lysate. Non-solubilized material is removed by centrifugation.

- SEPHAROSE 4B beads conjugated with anti-beta galactosidase are purchased from Promega. The beads are packed in columns and washed successively with phosphate-buffered saline with 0.02% sodium azide and TX  
15 buffer (10 mM Tris buffer, pH 7.4, 1% aprotinin). The clarified lysates are loaded on the SEPHAROSE columns, the ends of the columns are closed, and the columns placed on a rotary shaker for 2 hours, at room temperature and 16 hours at 4°C. After the columns settle, they are washed with TX buffer. The fused proteins are eluted with 0.1 M carbonate/bicarbonate buffer, pH10. The  
20 eluate from each affinity column is concentrated by ultrafiltration using, for example, CENTRICON-30 cartridges. The final protein concentrate is resuspended in PBS buffer.

- The individually purified fusion proteins are injected subcutaneously in Freund's adjuvant in rabbits. 1 mg of fused protein is injected at days 0 and 21,  
25 and rabbit serum is collected on days 42 and 56.

Control rabbits are similarly immunized with purified glutathione S-transferase (Sj26) protein obtained from control bacterial lysate and purified  $\beta$ -galactosidase obtained from commercial sources.

- Minilysates are prepared (essentially as described above for the fusion  
30 proteins but omitting the affinity purification steps) from the following transformed bacterial cultures: (1) cells transformed with the CAP37/glutathione S-transferase fusion-encoding plasmid; (2) cells transformed

with the glutathione S-transferase encoding plasmid; (3) cells transformed with each of the CAP37 peptide/ $\beta$ -galactosidase fusion-encoding plasmids (Example 11); and, (4) cells transformed with the  $\beta$ -galactosidase fusion-encoding plasmid. The minilysates and purified CAP37 protein were fractionated by SDS-PAGE, and the bands transferred to nitrocellulose filters for Western blotting (Ausubel et al.).

Serum from control (Sj26) rabbits is expected to be immunoreactive with each of the Sj26 and Sj26 fused protein antigens. Serum from the animal immunized with CAP37/Sj26 fused protein is expected to be reactive with Sj26, Sj26 fused protein antigen, and purified CAP37 indicating some specific immunoreaction with CAP37. The serum from the animal immunized with CAP37/Sj26 fused protein may also immunoreact with the CAP37 peptide/ $\beta$ -galactosidase antigens, but is not expected to react with  $\beta$ -galactosidase antigen alone.

Serum from control ( $\beta$ -galactosidase) rabbits is expected to be immunoreactive with each of the  $\beta$ -galactosidase and  $\beta$ -galactosidase fused protein antigens. Serum from the animal immunized with CAP37/ $\beta$ -galactosidase fused protein is expected to be reactive with  $\beta$ -galactosidase,  $\beta$ -galactosidase-fused protein antigen, and purified CAP37 indicating some specific immunoreaction with CAP37. The serum from the animal immunized with CAP37/ $\beta$ -galactosidase fused protein may also immunoreact with the CAP37 peptide/Sj26 antigens, but is not expected to react with Sj26 antigen alone.

#### VI. HYBRID PROTEINS CREATED WITH CAP37 PROTEIN

In another aspect, the invention includes CAP37 fused at its amino or carboxy end with a second protein or peptide to form a hybrid protein. The CAP37 protein making up the hybrid protein is preferably recombinantly produced CAP37 protein or a bioactive portion thereof, as described above.

The hybrid CAP37 protein or bioactive peptide (CAP37 protein/peptide) may be formed by chemical conjugation or by recombinant techniques. In the former method, the second peptide and CAP37 protein/peptide are modified by conventional coupling agents for covalent attachment (Duncan; Cumber).

Where CAP37 protein/bioactive peptide is used in tumor therapy, the protein/peptide may be advantageously fused with a polyclonal or monoclonal antibody specifically directed against target tumor-specific cell surface antigen(s). This fusion protein is then infused at or near the tumor site to attract monocytes  
5 to the site.

As an alternative chemical conjugation method, CAP37 protein/peptides not containing cysteine may be prepared to contain cysteine to allow disulfide coupling of the CAP37 protein to an activated second protein, thus simplifying the coupling reaction. The expression vector used for production of  
10 recombinant CAP37 bioactive peptide can be modified for insertion of an internal or a terminal cysteine codon according to standard methods of site-directed mutagenesis or oligonucleotide linker insertion.

In a preferred method, the hybrid protein is prepared recombinantly using an expression vector in which the coding sequence of the fusion peptide is  
15 joined to the CAP37 protein/bioactive peptide coding sequence. For example, an expression vector formed is designed to contain the following components: (a) a synthetic trp/lac promoter positioned appropriately ahead of a ribosome binding site that is also positioned appropriately ahead of an ATG start codon which is 5' to an cloning site; (b) the ricin A chain coding sequence (Olmes;  
20 Olmes et al.; Lamb et al.); (c) a spacer encoding sequence coding for 10 proline residues, which spaces the ricin A chain and CAP37 protein/peptide moieties; (d) the coding sequence for the CAP37 protein/peptide; and, (e) a stop codon positioned adjacent the carboxy-terminal codon of CAP37 protein/peptide. The method generally follows that used in fusing a soluble CD4 to domains 2 and 3  
25 of pseudomonas exotoxin A, as described previously (Chaudhary).

The expression vector containing the fusion protein coding sequences is analyzed for expression of the hybrid protein. Briefly, the expression vector is cultured in a suitable bacterial host under IPTG induction conditions to a desired cell density. The cells are harvested, ruptured by sonication, and the cell  
30 material is clarified by centrifugation. The clarified material is tested for (a) chemotactic ability, to confirm CAP37 protein/bioactive peptide activity, and (b) for ribosome inhibition activity, to confirm the ricin A chain enzymatic activity.

The protein may be purified by molecular-sieve and ion-exchange chromatography methods, with additional purification by polyacrylamide gel electrophoretic separation and/or HPLC chromatography, if necessary.

The ricin/CAP37 fusion protein can be used as a very specific anti-tumor  
5 reagent for cancers of monocyte cells.

It will be appreciated from the above how other second protein-CAP37 protein/peptide fusion proteins may be prepared. One variation on the above fusion is to exchange positions of the ricin A chain and CAP37 protein/peptide coding sequences in the fusion protein expression vector. Other variations  
10 would use abrin A chain or trichosanthin rather than ricin A chain. (Olmes et al., 1982; Lifson et al., 1989; Chow et al., 1990; Collins et al., 1990).

#### VII. UTILITY

The cloning and expression of human CAP37 protein provides an  
15 important source of the purified protein by simplifying preparation and allowing production of large quantities of the protein.

The purified CAP37 protein, and especially bioactive peptides derived from CAP37, can be applied to wound sites resulting in a two-fold benefit: (i) the protein and certain bioactive peptides (Example 13) are strong anti-microbial  
20 agents and (ii) monocytes are attracted to the wound site by the mature protein and certain bioactive peptides (Example 12). The CAP37 protein or bioactive peptide derived from CAP37 can be applied at a wound site by infusion, allowing the protein to form a gradient in surrounding tissue by diffusion.

Alternatively, the protein or peptide can be administered by routes known to  
25 one skilled in the art, such as parenterally (including subcutaneously) or orally (such as by tablet, in a microencapsulated form or in a mouthwash).

Importantly, the CAP37 protein or peptide derived from CAP37 can be formulated in a topical medication, such as pastes, gels, creams, and ointments, by standard methods (e.g., West et al.). The topical medication is then applied  
30 at the wound site: this method of application allows a controlled release of the protein at the wound site. Such topical formulations may also contain other components, such as antibiotics or epidermal growth factor (Brown et al.), to



facilitate healing. Further, the application may contain more than one peptide derived from CAP37 to advantageously take advantage of peptides having chemotactic activity and peptides having antibacterial activity that is superior to that of the mature CAP37 protein. Of course, as known in the art, these

5 peptides may be designed with amino acid residues attached to either one or both termini which will not alter its chemotactic and/or antibiotic function but will increase its longevity and alter its cytotoxicity.

Because of the bactericidal activity of these compounds, particularly the peptides derived from CAP37 disclosed above, against a wide variety of both

10 gram negative and gram positive bacteria, these compounds are particularly useful for treating infection caused by bacteria, particularly various *Pseudomonads*, *E. faecalis*, *E. coli*, and *Salmonella typhimurium* bacterial species. Because these peptides are active against gram negative bacteria, these compounds are especially useful in dental applications.

15 The purified CAP37 protein, or a bioactive peptide thereof, may also be used in treating other diseases such as cancers. CAP37 can be administered through systemic injection, intravesical administration or may be injected locally into an accessible tumor mass. The route of administration would depend on the nature and size of the tumor or other diseased tissue being treated. CAP37,

20 or a bioactive peptide thereof, could be administered using protocols for adjuvant immunotherapy currently using bacterial vaccines such as Bacille Calmette-Guerin (BCG) or *Corynebacterium parvum*. Such protocols are well known in the art. (Regelson et al., 1986;; Martinez-Piñero et al., 1988; Cumming et al., 1989).

25 Essentially, an effective amount of CAP37 or peptide derived from CAP37 would be mixed with a suitable pharmaceutically acceptable solvent or carrier and administered to an animal by one of the routes of administration established for other adjuvants such as BCG. CAP37 could be encapsulated in multilamellar phospholipid vesicles, or other encapsulating material, to aid in

30 administration. Depending on the area to be treated, the route of administration and the dose, CAP37 might be administered without a carrier.

An effective dose of CAP37 or peptide derived from CAP37 would vary depending upon the route of administration and the area to be treated. CAP37 or a peptide derived from CAP37 could be administered systemically or intraperitoneally in a dose of 100 ng/kg. Effective doses preferably fall in the  
5 range of 1  $\mu$ g to 1 mg per treatment.

Because of its ability specifically to attract monocytes, CAP37 or peptides derived from CAP37 could be used to treat any disease involving monocyte localization. These diseases would include neoplastic diseases, rheumatoid arthritis, hepatitis, chronic obstructive pulmonary disease, chronic periodontal  
10 disease, parasitic diseases such as malaria, tuberculosis and leprosy. CAP37 could also be used to treat diseases involving defects of monocyte chemotaxis such as Wiscott Aldrich syndrome, chronic mucocutaneous candidiasis, chronic granulomatous disease, Chediak Higashi syndrome, specific granule deficiency, systemic lupus erythematosus and herpes simplex.

15 Since the CAP37 protein or peptides derived from CAP37 bind bacterial lipopolysaccharide, CAP37 protein, or a bioactive peptide thereof, may also provide an effective treatment for endotoxemia. A solution of the CAP37 protein may be parenterally applied to a patient to bind endotoxins that are circulating in blood and facilitate their clearing. Particularly useful is  
20 prophylactic treatment before surgery with the CAP37 mature protein or LPS-binding peptides derived from CAP37 to prevent endotoxemia. Topical treatment prior to eye surgery may be especially useful to control the gram negative bacterial associated with eye infections.

Further, as discussed above (Section VI), hybrid proteins containing  
25 CAP37 protein, or bioactive portions thereof, may be useful in tumor therapies.

Purified antibodies specifically reactive with the CAP37 mature protein or bioactive peptides derived from CAP37 can be used to detect the presence and amount of CAP37 and/or CAP37 peptides. Further, these antibodies can be used to screen patients for diagnostic purposes.

30 The examples illustrate, but are in no way intended to limit the present invention. Although the invention has been described with reference to specific methods and compositions, it will be apparent to one skilled in the art how

various modifications and applications of the methods may be made without departing from the invention.

## 5 REFERENCES

- Ausubel, F. M., et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley and Sons, Inc., Media PA.
- Benfey, P. N., et al., *J. Biol. Chem.* 262:5377 (1987).
- 10 Berman, P. W., et al., *Science* 222:524 (1983).
- Bing, D. H., et al., *Ann. N.Y. Acad. Sci.* 485:104 (1984).
- Boyum, A., *J. Clin. Lab. Invest.* 21:SUP97:77 (1968).
- Bradford et al., *Anal. Biochem.* 72:248-254, 1976.
- Brake, A. J., U. S. Patent No. 4,870,008, issued September 26, 1989.
- 15 Brake, A. J., et al., *Proc. Natl. Acad. Sci. USA* 81:5330 (1984).
- Brown, G. L., et al., *Ann. Surg.* 208(6):788 (1988).
- Cates, K. L., et al., p67 IN LEUKOCYTE CHEMOTAXIS, edited by J. I. Gallin and P. G. Quie, Raven Press NY (1978).
- Chambers, W. M., et al., *Met. Immunol. Immunopathol.* 5:197 (1983).
- 20 Chang, C. N., et al., *Mol. Cell. Biol.* 6:1812 (1986).
- Chaudhary, V.K., et al., *Nature*, 335:369 (1988).
- Chirgwin, J. M., et al., *Biochem.*, 18:5294 (1979).
- Chow, C. C., et al., *J. Biol. Chem.*; 265: 8670-8674 (1990).
- Collins, E. J., et al., *J. Biol. Chem.* 265: 8665-8669 (1990).
- 25 Cumber, J.A., et al., *Methods in Enzymology*, 112:207 (1985).
- Cumming et al., *Brit. J. Urology*, 63: 259-263 (1989).
- Duncan, R.J.S., et al., *Anal Biochem*, 182:68 (1983).
- Gershenfeld, H. K., et al., *Science* 232:854 (1986).
- Gillis, S., et al., *Behring. Inst. Mitt.*, 83:1 (1988).
- 30 Gluzman, Y., *Cell*, 23:175 (1981).
- Gray, P. W., et al., *Nature*, 295:503 (1982).
- Grunstein, M., et al., *Methods in Enzymology*, 68:379 (1979).

- Guarente, L., *Methods in Enzymology*, 101:181 (1983).
- Hayashi, H., et al., *Int. Rev. Cytol.*, 89:179 (1984).
- Herbert, W. J., in *THE HANDBOOK OF EXPERIMENTAL IMMUNOLOGY*, Second Edition, edited by D. M. Weir, Blackwell Scientific Publications, Oxford, England (1973).
- 5 Hopp, T. P., et al., *Proc. Natl Acad. Sci. USA*, 78:3824 (1981).
- Hoylaerts, M., et al., *FEBS Lett.*, 204:83 (1986).
- Hurley, J. V., et al., in *ACUTE INFLAMMATION*, second edition, p109, published by Churchill Livingstone, Edinburgh (1983).
- 10 Johnson, D. M. A., et al., *FEBS*, 166:347 (1984).
- Jones, E. W., *Ann. Rev. Genetics*, 18:233 (1984).
- Kawaguchi, T., et al., *Am. J. Pathol.* 115:307 (1984).
- Kingsman, A. J., et al., U. S. Patent No. 4,615,974, issued October 7, 1986.
- Kopchick, J. J., et al., U. S. Patent No. 4,828,987, issued May 9, 1989.
- 15 Kurjan, J., et al., U. S. Patent No. 4,546,082, issued October 8, 1985.
- Lacy, M. J., et al., *J. Immunol. Methods*, 87:169 (1986).
- Lamb, F.I., et al., *Eur J Biochem.*, 148:265 (1985).
- Laemmli, *Nature*, 227:680 (1970).
- Lemontt, J. F., et al., *DNA*, 4:419 (1985).
- 20 Lifson, J.D. et al., U.S. Patent No. 4,795,739, issued January 3, 1989.
- Lobe, C. G., et al., *Science*, 232:858 (1986).
- Maniatis, T., et al., *MOLECULAR CLONING: A LABORATORY MANUAL*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY (1982).
- Martinez-Piñero et al., *Eur. Urol.*, 15:146-149, 1988.
- 25 Maruyama, T., et al., *Nucleic Acids Res.*, 14(s) r151-r197.
- McGrogan, M., et al., *Biotech.*, 6:172 (1988 A).
- McGrogan, M., et al., *J. Exp. Med.*, 168:2295 (1988 B).
- McIvor, R. S., et al., *Mol. Cell. Biol.*, 5:1349 (1985).
- Messing, J., *Methods in Enzymology*, 101:20 (1983).
- 30 Miller, J. H., *EXPERIMENTS IN MOLECULAR GENETICS*, Cold Spring Harbor Laboratories, Cold Spring Harbor NY (1972).
- Moriarty, A. M., et al., U. S. Patent No. 4,777,240, issued October 11, 1988.

- Mullis, K., U. S. Patent No. 4,683,202, issued July 28, 1987.
- Nieman, M. A., et al., *Biochem.*, 23:2482 (1984).
- Oeda, K., et al., U. S. Patent No. 4,766,068, issued August 23, 1988.
- Okano, K., et al., *J. Biochem.*, 102:13 (1987).
- 5 Okayama, H., et al., *Mol. Cell. Biol.*, 2:161 (1982).
- Olnes, S., *Nature*, 328:474 (1987).
- Olnes, S., et al., in MOLECULAR ACTION OF TOXINS AND VIRUSES, (Elsevier, 1982), Chapter 3.
- Olnes, S., et al., "Toxic Lectins and Related Proteins", in Cohen, P. et al. (eds.),
- 10 MOLECULAR ACTION OF TOXINS AND VIRUSES, Elsevier Biomedical Press, 1982, pp. 55-105.
- Patzer, E. J., et al., *J. Virol.*, 58:884 (1986).
- Pereira, H. A., et al., *J. Immunol. Methods*, 117:115 (1989).
- Regelson et al., *Clin. Sci. Rev.* for (1): 29-42, 1986.
- 15 Revel, M., et al., U. S. Patent No. 4,889,803, issued December 26, 1989.
- Salvesen, G., et al., *Biochem.*, 26:2289 (1987).
- Scharf, S. J., et al., *Science*, 233:1076 (1986).
- Scholtissek, S., et al., *Gene*, 62(1):55 (1988).
- Seed, B., *Proc. Natl. Acad. Sci. USA*, 84:8573 (1987).
- 20 Shafer, W. M., et al., *Infect. Immun.*, 45:29 (1984).
- Shafer, W. M., et al., *Infect. Immun.*, 53:651 (1986).
- Sinha, S., et al., *Proc. Natl. Acad. Sci. USA*, 84:2228 (1987).
- Simonsen, C. C., et al., *Proc. Natl. Acad. Sci. USA*, 80:2495 (1983).
- Smith, D. B., et al., *Gene*, 67(1):31 (1988).
- 25 Snyderman et al., *J. Exp. Med.*, 134:1131 (1971).
- Snyderman, R., et al., p73 in LEUKOCYTE CHEMOTAXIS, edited by J. I. Gallin and P. G. Quie, Raven Press NY (1978).
- Spitznagel, J. K., et al., *J. Immunol.*, 139:1291 (1987).
- Thim, L., et al., *FEBS Lett.*, 212:2, 307 (1987).
- 30 Towbin et al., *Proc. Natl. Acad. Sci. USA*, 76:4350-4354 (1979).
- Ullmann, A., *Gene*, 29(1-2):27 (1984).
- Urlaub, G., et al., *Proc. Natl. Acad. Sci. USA*, 77:4216 (1980).

- Warren, H. S., et al., pages 341-348 in DETECTION OF BACTERIAL ENDOTOXINS WITH THE LIMULUS AMEBOCYTE LYSATE TEST, published by Alan R. Liss, Inc. (1987).
- West, G. III, et al., U. S. Patent No. 4,781,871, issued November 1, 1988.
- 5    Wilkinson, P. C., et al., in ACUTE INFLAMMATION, second edition, p119, published by Churchill Livingstone, Edinburgh (1983).
- Woo, S. L. C., *Methods in Enzymology*, 68:389 (1979).
- Wood, W. I., et al., *Nature*, 312:330 (1984).
- Woodbury, R. G., et al., *Biochem.*, 17:811 (1978).
- 10    Wright, D. G., et al., *J. Immunol.*, 119:1068 (1977).
- Zigmond, S., et al., *J. Exp. Med.*, 137:387 (1973).
- Zsebo, K. M., et al., *J. Biol. Chem.*, 261:5858 (1986).

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Pereira, Heloise Anne  
Spitznagel, John K.
- (ii) TITLE OF INVENTION: Chemotactic, Antibiotic and  
Lipopolysaccharide-Binding Peptide Fragments of CAP37
- 10 (iii) NUMBER OF SEQUENCES: 29
- (iv) CORRESPONDENCE ADDRESS:  
15 (A) ADDRESSEE: Needle & Rosenberg, P.C.  
(B) STREET: 133 Carnegie Way N.W., Suite 400  
(C) CITY: Atlanta  
(D) STATE: Georgia  
(E) COUNTRY: USA  
(F) ZIP: 30303
- 20 (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
25 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER: US  
(B) FILING DATE: 18-MAR-1992  
30 (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:  
(A) APPLICATION NUMBER: US 07/543,151  
(B) FILING DATE: 25-JUN-1990
- 35 (vii) PRIOR APPLICATION DATA:  
(A) APPLICATION NUMBER: US 07/375,739  
(B) FILING DATE: 05-JUL-1989
- 40 (viii) ATTORNEY/AGENT INFORMATION:  
(A) NAME: Severson, Mary L.  
(B) REGISTRATION NUMBER: 34,927  
(C) REFERENCE/DOCKET NUMBER: 0510.024
- 45 (ix) TELECOMMUNICATION INFORMATION:  
(A) TELEPHONE: (404) 688-0770  
(B) TELEFAX: (404) 688-9880
- 50

70

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 8 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

10 (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE: 115-122aa of mature CAP37 protein

## 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ala Thr Val Glu Ala Gly Thr Arg  
1 5

## 20 (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 21 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30 (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE: 102-122aa of mature CAP37 protein

## 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Thr Ser Ser Val Thr Ile Leu Pro Leu Pro Leu Gln Asn Ala Thr Val  
1 5 10 15

40 Glu Ala Gly Thr Arg  
20

## (2) INFORMATION FOR SEQ ID NO:3:

## 45 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE: 133-141aa of mature CAP37 protein

55



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ser Gly Gly Arg Leu Ser Arg Phe Pro  
1 5 10

5

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

10

(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

15

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE: 130-143aa of mature CAP37 protein

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ser Gln Arg Ser Gly Gly Arg Leu Ser Arg Phe Pro Arg Phe  
1 5 10

25 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

30

(A) LENGTH: 7 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

35

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE: 45-51aa of mature CAP37 protein

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ser Gln Asn Pro Gly Val Ser  
1 5

45

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

50

(A) LENGTH: 11 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

55

(vi) ORIGINAL SOURCE: 43-53aa of mature CAP37 protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

5 Phe Gln Ser Gln Asn Pro Gly Val Ser Thr Val  
 1 5 10

## (2) INFORMATION FOR SEQ ID NO:7:

10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE: 23-42aa of mature CAP37 protein

20

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

25 Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe Val Met Thr  
 1 5 10 15  
 Ala Ala Ser Cys  
 20

## (2) INFORMATION FOR SEQ ID NO:8:

30 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 25 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

40 (vi) ORIGINAL SOURCE: 20-44aa of mature CAP37 protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

45 Asn Gln Gly Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe  
 1 5 10 15  
 Val Met Thr Ala Ala Ser Cys Phe Gln  
 20 25

50

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 222 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10 (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

15 Ile Val Gly Gly Arg Lys Ala Arg Pro Arg Gln Phe Pro Phe Leu Ala  
1 5 10 15  
20 Ser Ile Gln Asn Gln Gly Arg His Phe Cys Gly Gly Ala Leu Ile His  
20 20 25 30  
35 Ala Arg Phe Val Met Thr Ala Ala Ser Cys Phe Gln Ser Gln Asn Pro  
35 40 45  
40 Gly Val Ser Thr Val Val Leu Gly Ala Tyr Asp Leu Arg Arg Arg Glu  
50 55 60  
45 Arg Gln Ser Arg Gln Thr Phe Ser Ile Ser Ser Met Ser Glu Asn Gly  
65 70 75 80  
50 Tyr Asp Pro Gln Gln Asn Leu Asn Asp Leu Met Leu Leu Gln Leu Asp  
85 90 95  
55 Arg Glu Ala Asn Leu Thr Ser Ser Val Thr Ile Leu Pro Leu Pro Leu  
100 105 110  
60 Gln Asn Ala Thr Val Glu Ala Gly Thr Arg Cys Gln Val Ala Gly Trp  
115 120 125  
65 Gly Ser Gln Arg Ser Gly Gly Arg Leu Ser Arg Phe Pro Arg Phe Val  
130 135 140  
70 Asn Val Thr Val Thr Pro Glu Asp Gln Cys Arg Pro Asn Asn Val Cys  
145 150 155 160  
75 Thr Gly Val Leu Thr Arg Arg Gly Gly Ile Cys Asn Gly Asp Gly Gly  
165 170 175  
80 Thr Pro Leu Val Cys Glu Gly Leu Ala His Gly Val Ala Ser Phe Ser  
180 185 190  
85 Leu Gly Pro Cys Gly Arg Gly Pro Asp Phe Phe Thr Arg Val Ala Leu  
195 200 205  
90 Phe Arg Asp Trp Ile Asp Gly Val Leu Asn Asn Pro Gly Pro  
210 215 220

74

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 26 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## 10 (v) FRAGMENT TYPE: N-terminal

## 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Thr Arg Leu Thr Val Leu Ala Leu Leu Ala Gly Leu Leu Ala Ser  
1 5 10 15

Ser Arg Ala Gly Ser Ser Pro Leu Leu Asp  
20 25

## (2) INFORMATION FOR SEQ ID NO:11:

## 25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## 30 (ii) MOLECULE TYPE: peptide

## (v) FRAGMENT TYPE: internal

## 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Cys Gln Val Ala Gly Trp Gly  
1 5

## 40 (2) INFORMATION FOR SEQ ID NO:12:

## (i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## 50 (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

55 CUGCCTCCYT GRTTYTGRAT  
20

75

## (2) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

15 ARGGAAGGGRA AYTGNCKGGG  
 20

## (2) INFORMATION FOR SEQ ID NO:14:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 150 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 1..150

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ATG CTG CTT CAG AGG TTT GTC AAC GTG ACT GTG ACC CCC GAG GAC CAG  
 48

40 Met Leu Leu Gln Arg Phe Val Asn Val Thr Val Thr Pro Glu Asp Gln  
 1 5 10 15

TGT CGC CCC ACC ACC GTG TGC ACC GGT GTG CTC ACC CGC CGC GGT GGC  
 96

45 Cys Arg Pro Asn Asn Val Cys Thr Gly Val Leu Thr Arg Arg Gly Gly  
 20 25 30

ATC TCG AAT GGG GAC GGG GGC ACC CCC CTC GTC TGC GAG CCG CTG GCC  
 144

50 Ile Cys Asn Gly Asp Gly Gly Thr Pro Leu Val Cys Glu Gly Leu Ala  
 35 40 45

CAC GGC

150

His Gly

55 50

## (2) INFORMATION FOR SEQ ID NO:15:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 50 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

10

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met Leu Leu Gln Arg Phe Val Asn Val Thr Val Thr Pro Glu Asp Gln  
 1 5 10 15  
 Cys Arg Pro Asn Asn Val Cys Thr Gly Val Leu Thr Arg Arg Gly Gly  
 20 25 30  
 Ile Cys Asn Gly Asp Gly Gly Thr Pro Leu Val Cys Glu Gly Leu Ala  
 35 40 45  
 His Gly  
 50

## 25 (2) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 37 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (v) FRAGMENT TYPE: internal

35

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

40 Ala Gly Thr Arg Cys Gln Val Ala Gly Trp Gly Ser Gln Arg Ser Gly  
 1 5 10 15  
 Gly Arg Leu Ser Arg Phe Pro Arg Phe Val Asn Val Thr Val Thr Pro  
 20 25 30  
 Glu Asp Gln Cys Arg  
 35

## 50 (2) INFORMATION FOR SEQ ID NO:17:

## (i) SEQUENCE CHARACTERISTICS:

- 55 (A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

77

(ii) MOLECULE TYPE: DNA (genomic)

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TGYCARGTNG CNGGNTGGGG  
20

10 (2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 125 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20

(ix) FEATURE:

- (A) NAME/KEY: CDS  
(B) LOCATION: 6..125

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

47 TGTAG GTT GCG GGT TGG GGG AGC CAG CAC AGT GGG GGG CGT CTC TCC  
30 Val Ala Gly Trp Gly Ser Gln His Ser Gly Gly Arg Leu Ser  
1 5 10  
CGT TTT CCC AGG TTC GTC AAC GTG ACT GTG ACC CCC GAG GAC CAG TGT  
95  
35 Arg Phe Pro Arg Phe Val Asn Val Thr Val Thr Pro Glu Asp Gln Cys  
15 20 25 30  
CGC CCC AAC AAC GTG TGC ACC GGT GTG CTC  
125  
40 Arg Pro Asn Asn Val Cys Thr Gly Val Leu  
35 40

45 (2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: protein

78

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Val Ala Gly Trp Gly Ser Gln His Ser Gly Gly Arg Leu Ser Arg Phe  
 1 5 10 15  
 5 Pro Arg Phe Val Asn Val Thr Val Thr Pro Glu Asp Gln Cys Arg Pro  
 20 25 30  
 10 Asn Asn Val Cys Thr Gly Val Leu  
 35 40

## (2) INFORMATION FOR SEQ ID NO:20:

## (i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 50 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

25 TGTCAGGTTG CGGGTTGGGG GAGCCAGCAC AGTGGGGGGC GTCTCTCCCG  
 50

## (2) INFORMATION FOR SEQ ID NO:21:

- 30 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 35 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

40

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ATCGTTGGCG GCCGGAAGGC G  
 21

45

## (2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 50 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)  
 55



## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

5 TTGGGCCCTG GCCCCGGTCG G  
21

## (2) INFORMATION FOR SEQ ID NO:23:

10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

20 ATGATCGTTG GCGCCGGAA GGCG  
24

## (2) INFORMATION FOR SEQ ID NO:24:

25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

35

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

ATGGGGGAGG GTGGGTCC  
18

40

## (2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 43 base pairs  
45 (B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

50

80

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

CCGGAATTCC AAGCTTCCAC CATGACCCGG CTGACAGTCC TGG  
43

5

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

10

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

20 CCGGATCCTC TAGACCCTAG GCTGGCCCCG GTCCCGG  
37

(2) INFORMATION FOR SEQ ID NO:27:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: DNA (genomic)

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GATCCGCCTG CAGGCCCTGT AAGCTTGAGG  
30

40 (2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

45

(A) LENGTH: 9 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

50

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

55

Ser Ile Ser Ser Met Ser Glu Asn Gly  
1 5

81

## (2) INFORMATION FOR SEQ ID NO:29:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## 10 (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

15

Ser Gln His Ser Gly Gly Arg Leu Ser Arg Phe Pro Arg Phe  
1 5 10

**IT IS CLAIMED:**

1. A peptide derived from the 115th to 122nd amino acid region of CAP37 having chemotactic activity for monocytes, comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:1.
2. The peptide of Claim 1, consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:2.
3. A peptide derived from the 133rd to 141st amino acid region of CAP37 having chemotactic activity for monocytes, comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:3.
4. The peptide of Claim 3, consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:4.
5. The peptide of Claim 3, consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:29.
6. A peptide derived from the 45th to 51st amino acid region of CAP37 having chemotactic activity for monocytes, comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:5.
7. The peptide of Claim 6, consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:6.
8. A peptide derived from the 23rd to 42nd amino acid region of CAP37 capable of binding bacterial lipopolysaccharide, comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:7.
9. The peptide of Claim 8, consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:8.

10. A peptide derived from the 23rd to 42nd amino acid region of CAP37 having antibacterial activity, comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:7.
11. The peptide of Claim 10 consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:8.
12. A DNA molecule, comprising a DNA sequence coding for a peptide derived from the 115th to 122nd amino acid region of CAP37, wherein the peptide comprises the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:1.
13. A DNA molecule, comprising a DNA sequence coding for a peptide derived from the 133rd to 141st amino acid region of CAP37, wherein the peptide comprises the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:3.
14. A DNA molecule, comprising a DNA sequence coding for a peptide derived from the 45th to 51st amino acid region of CAP37, wherein the peptide comprises the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:5.
15. A DNA molecule, comprising a DNA sequence coding for a peptide derived from the 23rd to 42nd amino acid region of CAP37, wherein the peptide comprises the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:7.
16. A method of treating a wound by the application of a topical medication comprising a peptide derived from CAP37 that is chemotactic for monocytes, wherein the peptide is present in the medication in a pharmacologically effective amount to promote wound healing.

17. The method of Claim 16, wherein the peptide derived from CAP37 is selected from the group consisting of a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:1; a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:3; a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:5; a peptide consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:2; a peptide consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:4; a peptide consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:6; and a peptide consisting of the amino acid sequence as defined the Sequence Listing by SEQ ID NO:29.
18. The method of claim 16, wherein the topical medication further comprises an epidermal growth factor in a pharmacologically effective amount to promote wound healing.
19. The method of claim 16, wherein the form of the topical medication is selected from the group consisting of pastes, gels, creams, and ointments.
20. A method for treating diseases involving monocyte localization or defects of monocyte chemotaxis in an animal comprising the step of administering to the animal a therapeutic composition comprising a pharmacologically effective amount of a monocyte chemotactic peptide derived from CAP37.
21. The method of Claim 20, wherein the peptide derived from CAP37 is selected from the group consisting of a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:1; a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:3; a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:5; a peptide consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:2; a peptide consisting of the amino acid sequence as defined in the Sequence Listing by

SEQ ID NO:4; a peptide consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:6; and a peptide consisting of the amino acid sequence as defined the Sequence Listing by SEQ ID NO:29.

22. The method of Claim 20, further comprising, a pharmaceutically acceptable carrier.

23. A method for treating diseases in animals involving monocyte localization or defects of monocyte chemotaxis comprising the step of administering to the animal a therapeutic composition comprising a pharmacologically effective amount of a monocyte chemotactic peptide derived from CAP37.

24. A method for increasing the migration of monocytes to a particular tissue site in an animal, comprising the step of administering to the tissue site a therapeutic composition comprising a pharmacologically effective amount of a monocyte chemotactic peptide derived from CAP37.

25. A method for treating infection at a particular tissue site in an animal, comprising the step of applying to the tissue site a topical medication comprising a peptide derived from CAP37 that is antibiotic, wherein the peptide is present in the medication in a pharmacologically effective amount to treat infection.

26. The method of Claim 25, wherein the peptide derived from CAP37 is selected from the group consisting of a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:7 and a peptide consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:8.

27. The method of Claim 25, wherein the infection is caused by a bacterial species selected from the group consisting of *Pseudomonads*, *E. faecalis*., *E. coli*, and *Salmonella typhimurium*.

28. The method of Claim 25, wherein the form of the topical medication is selected from the group consisting of pastes, gels, creams, and ointments.
29. A method for treating infection in animals, comprising the step of administering to the animal a therapeutic composition comprising a pharmacologically effective amount of a antibiotic peptide derived from CAP37.
30. The method of Claim 29, wherein the antibiotic peptide derived from CAP37 is selected from the group consisting of a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:7 and a peptide consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:8.
31. A method for treating or preventing endotoxemia in animals, comprising the step of administering to the animal a therapeutic composition comprising a pharmacologically effective amount of a lipopolysaccharide-binding peptide derived from CAP37.
32. The method of Claim 31, wherein the antibiotic peptide derived from CAP37 is selected from the group consisting of a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:7 and a peptide consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:8.
33. A purified antibody specifically reactive to a peptide derived from CAP37, wherein the peptide is selected from the group consisting of a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:1; a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:3; a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:5; a peptide comprising the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:7; a peptide consisting of the amino acid sequence as defined in the




Sequence Listing by SEQ ID NO:2; a peptide consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:4; a peptide consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:6; and a peptide consisting of the amino acid sequence as defined in the Sequence Listing by SEQ ID NO:8.

3


ד

•

2/17

CAP 37-A SPECIFIC  
MONOCYTE CHEMOTAXIN**Figure 2**

3/17

**Figure 3**

SUBSTITUTE SHEET


4/17

	10	10	20
CAP 37	I-V-G-G-R-K-A-R-P-R-Q-F-P-F-L-A-S-I-Q-N-Q-G-R-H-F----		
ELAST	I-V-G-G-R-R-A-R-P-H-A-W-P-F-M-V-S-L-Q-L-R-G-G-H-F----		
FACTD	I-L-G-G-R-E-A-E-A-H-A-R-P-Y-M-A-S-V-Q-L-N-G-A-E-L----		
PLASM	I-V-G-G-C-V-S-K-P-H-S-W-P-W-Q-V-S-L-R-R-S-S-R-H-F----		
CATG	I-I-G-G-R-E-S-R-P-H-S-R-P-Y-M-A-Y-L-Q-I-Q-S-P-A-G-Q-		
RMCP1	I-I-G-G-V-E-S-R-P-H-S-R-P-Y-M-A-H-L-E-I-T-T-E-R-G-Y-		
CCPI	I-I-G-G-H-E-V-K-P-H-S-R-P-Y-M-A-L-L-S-I-K-D-Q-Q-P-E-		
HF	I-I-G-G-D-T-V-V-P-H-S-R-P-Y-M-A-L-L-K-L-S-S-N-T-----		

	▼	*	▼
CAP37	-----C-G-G-A-L-I-H-A-R-F-V-M-T-A-A-S-C-		42
ELAST	-----C-G-A-T-L-I-A-P-N-F-V-M-S-A-A-H-C-		42
FACTD	-----C-G-G-V-L-V-A-E-Q-W-V-L-T-A-A-H-C-		42
PLASM	-----C-G-G-T-L-I-S-P-K-W-V-L-T-A-A-H-C-		42
CATG	S-R---C-G-G-F-L-V-R-E-D-F-V-L-T-A-A-H-C-		45
RMCP1	K-A-T-C-G-C-F-L-V-N-R-N-F-V-M-T-A-A-H-C-		46
RMCP1I	R-V-I-C-G-G-F-L-I-S-R-Q-F-V-L-T-A-A-H-C-		46
CCPI	A---I-C-G-G-F-L-I-R-E-D-F-V-L-T-A-A-H-C-		45
HF	----I-C-A-G-A-L-I-E-K-N-W-V-L-T-A-A-H-C-		42

Figure 4

5/17



T7 PRIMER →  
 CMV/T7 PROMOTERS → +1  
 CTATAGTGAGTCGTATTAGAGACCGGAAGCTT

KpnI SacI BamHI SpeI XmaIII  
 GGTACCGAGCTCGGATCCACTAGTAACGGCCG

BstXI EcoRI PstI EcoRV BstXI  
 CCAGTGTGCTGGAATTCTGCAGATATCCATCACA CTG

NcoI XhoI SphI XbaI ApaI +1 ← Sp6 PROMOTER  
 GCGGCCGCTCGAGCATGCATCTAGAGGGCCCTATAGTGTACCTAAAT

**Figure 5****SUBSTITUTE SHEET**

6/17

ATCTGTGCTAGGGCCCGGCTGCCAGGGCAGAACTCAGACTTAAAGCACAGAGAAG	CC	2
GCAAGCGGCTTGGCCTGGGTACACAGCCAGCCCGGCTGGACGATCCCGCGAAA	57	112
GGCGTGAGGGCGGACGGTGTGCGGGACTCAGGGGCCCCCTGTCTCTTAGGGAG	168	211
TGGGACG ATG GGG GAG GGT GGG TCC CCC CGC AGC CCC ACT GGG		
MET Gly Glu Gly Gly Ser Pro Arg Ser Pro Thr Gly		
-48	-37	
TGG ATA GAG CTG AGG CTG CAG CTT CAC ACC CCC TCC CGG CCA	253	
Trp Ile Glu Leu Arg Leu Gln Leu His Thr Pro Ser Arg Pro		
-23		
CTG TGT GGA TTC TTG GGG ATC TCA GAG CTG TCT CCC CCC GAC	295	
Leu Cys Gly Phe Leu Gly Ile Ser Glu Leu Ser Pro Pro Asp		
-9		
CCA GGC TCC AGC CCC CTT TTG GAC ATC GTT GGC GGC CGG AAG	337	
Pro Gly Ser Ser Pro Leu Leu Asp Ile Val Gly Gly Arg Lys		
1	6	
GCG AGG CCC CGC CAG TTC CCG TTC CTG GCC TCC ATT CAG AAT	379	
Ala Arg Pro Arg Gln Phe Pro Phe Leu Ala Ser Ile Gln Asn		
20		
CAA GGC AGG CAC TTC TGC GGG GGT GCC CTG ATC CAT GCC CGC	421	
Gln Gly Arg His Phe Cys Gly Gly Ala Leu Ile His Aln Arg		
34		
TTC GTG ATG ACC GCG GCC AGC TGC TTC CAA AGC CAG AAC CCC	463	
Phe Val MET Thr Ala Ala Ser Cys Phe Gln Ser Gln Asn Pro		
48		
GGG GTT AGC ACC GTG GTC CTG GGT GCC TAT GAC CTG AGG CGG	505	
Gly Val Ser Thr Val Val Leu Gly Ala Tyr Asp Leu Arg Arg		
62		
CGG GAG AGG CAG TCC CGC CAG ACG TTT TCC ATC AGC AGC ATG	547	
Arg Glu Arg Gln Ser Arg Gln Thr Phe Ser Ile Ser Ser MET		
76		
AGC GAG AAT GGC TAC GAC CCC CAG CAG AAC CTG AAC GAC CTG	589	
Ser Glu Asn Gly Tyr Asp Pro Gln Gln Asn Leu Asn Asp Leu		
90		
ATG CTG CTT CAG AGG TTT GTC AAC GTG ACT GTG ACC CCC GAG	631	
MET Leu Leu Gln Arg Phe Val Asn Val Thr Val Thr Pro Glu		
104		
GAC CAG TGT CGC CCC AAC AAC GTG TGC ACC GGT GTG CTC ACC	673	
Asp Gln Cys Arg Pro Asn Asn Val Cys Thr Gly Val Leu Thr		
118		
CGC CGC GGT GGC ATC TGC AAT GGG GAC GGG GGC ACC CCC CTC	715	
Arg Arg Gly Gly Ile Cys Asn Gly Asp Gly Gly Thr Pro Leu		
132		
GTC TGC GAG GGC CTG GCC CAC GGC GTG GCC TCC TTT TCC CTG	757	
Val Cys Glu Gly Leu Ala His Gly Val Ala Ser Phe Ser Leu		
146		
GGG CCC TGT GGC CGA GGC CCT GAC TTC TTC ACC CGA GTG GCG	799	
Gly Pro Cys Gly Arg Gly Pro Asp Phe Phe Thr Arg Val Ala		
160		
CTC TTC CGA GAC TGG ATC GAT GGT GTT CTC AAC AAC CCG GGA	841	
Leu Phe Arg Asp Trp Ile Asp gly Val Leu Asn Asn Pro Gly		
174		
CCG GGG CCA GCC TAG GGGGGCTGTGACCTCCCATGGAGCCCAGCCCCGC	891	
Pro Gly Pro Ala End		
178		
CCTCCACACCTCCGGCGCTCCGCACCCACCTCCACGGCCCCCGCCCTGCCCCCG	946	
TCCGGCCAGAGGGGCCCTGGCTGTAATAAAGAAGCCGATCTCTCTCTGAAA	998	

Figure 6

SUBSTITUTE SHEET

7/17


CCC ATG ACC CGG CTG ACA GTC CTG GCC CTG CTG GCT GGT CTG	42
MET Thr Arg Leu Thr Val Leu Ala Leu Leu Ala Gly Leu	
-26 ↓ -14	
CTG GCG TCC TCG AGG GCC GGC TCC AGC CCC CTT TTG GAC ATC	84
Leu Ala Ser Ser Arg Ala Gly Ser Ser Pro Leu Leu Asp Ile	
GTT GGC GGC CGG AAG GCG AGG CCC CGC CAG TTC CCG TTC CTG	126
Val Gly Gly Arg Lys Ala Arg Pro Arg Gln Phe Pro Phe Leu	
GCC TCC ATT CAG AAT CAA GGC AGG CAC TTC TGC GGG GGT GCC	168
Ala Ser Ile Gln Asn Gln gly Arg His Phe Cys Gly Gly Ala	
CTG ATC CAT GCC CGC TTC GTG ATG ACC GCG GCC AGC TGC TTC	210
Leu Ile His Ala Arg Phe Val MET Thr Ala Ala Ser Cys Phe	
CAA ACC CAG AAC CCC GGG GTT AGC ACC GTG GTG CTG GGT GCC	252
Gln Ser Gln Asn Pro Gly Val Ser Thr Val Val Leu Gly Ala	
TAT GAC CTG AGG CGG CGG GAG AGG CAG TCC CGC CAG ACG TTT	294
Tyr Asp Leu Arg Arg Arg Glu Arg Gln Ser Arg Gln Thr Phe	
TCC ATC AGC AGC ATG AGC GAG AAT GGC TAC GAC CCC CAG CAG	336
Ser Ile Ser Ser MET Ser Glu Asn Gly Tyr Asp Pro Gln Gln	
AAC CTG AAC GAC CTG ATG CTG CTT CAG CTG GAC CGT GAG GCC	378
Asn Leu Asn Asp Leu MET Leu Leu Gln Leu Asp Arg Glu Ala	
AAC CTC ACC AGC AGC GTG ACG ATA CTG CCA CTG CCT CTG CAG	420
Asn Leu Thr Ser Ser Val Thr Ile Leu Pro Leu Pro Leu Gln	
AAC GCC ACG GTG GAA GCC GGC ACC AGA TGC CAG GTG GCC GGC	462
Asn Ala Thr Val Glu Ala Gly Thr Arg Cys Gln Val Ala Gly	
TGG GGG AGC CAG CGC AGT GGG GGG CGT CTC TCC CGT TTT CCC	504
Trp Gly Ser Gln Arg Ser Gly Gly Arg Leu Ser Arg Phe Pro	
AGG TTT GTC AAC GTG ACT GTG ACC CCC GAG GAC CAG TGT CGC	546
Arg Phe Val Asn Val Thr Val Thr Pro Glu Asp Gln Cys Arg	
CCC AAC AAC GTG TGC ACC GGT GTG CTC ACC CGC CGC GGT GGC	588
Pro Asn Asn Val Cys Thr Gly Val Leu Thr Arg Arg Gly Gly	
ATC TGC AAT GGG GAC GGG GGC ACC CCC CTC GTC TGC GAG GGC	630
Ile Cys Asn Gly Asp Gly Gly Thr Pro Leu Val Cys Glu Gly	
CTG GCC CAC GGC GTG GCC TCC TTT TCC CTG GGG CCC TGT GGC	672
Leu Ala His gly Val Ala Ser Phe Ser Leu Gly Pro Cys Gly	
CGA GGC CCT GAC TTC TTC ACC CGA GTG GCG CTC TTC CGA GAC	714
Arg Gly Pro Asp Phe Phe Thr Arg Val Ala Leu Phe Arg Asp	
TGG ATC GAT GGT GTT CTC AAC AAC CCG GGA CCG GGG CCA GCC	756
Trp Ile Asp Gly Val Leu Asn Asn Pro Gly Pro Gly Pro Ala	
TAG GGGGGCCTGTGACCTCCCATGGAGCCAGCCCCGCCCTCCACACCTCCGGC	810
End	
GCTCCGCACCCACCTCCACGGCCCCGCCCTGCCCGTCCGGCCAGAGGGGCC	865
CTGGCTGTAATAAAGAAGCCGATCTCTCTGAAAAAAA	905

Figure 7


SUBSTITUTE SHEET




8/17

**Figure 8****SUBSTITUTE SHEET**


9/17

**Figure 9**

10/17

**Figure 10****SUBSTITUTE SHEET**

11/17


**Figure 11**

SUBSTITUTE SHEET

BEST AVAILABLE COPY

12/17


Figure 12



SUBSTITUTE SHEET

BEST AVAILABLE COPY


Figure 13



Percent Killed  
SUBSTITUTE SHEET

BEST AVAILABLE COP

Figure 14



15/17





Figure 15

SUBSTITUTE SHEET

BEST AVAILABLE COPY





16/17

**Figure 16**

SUBSTITUTE SHEET

BEST AVAILABLE COPY

17/17



SUBSTITUTE SHEET

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/02580

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C07K 07/04, 07/06, 07/08, 07/10, 13/00; A61K 37/02; C12N 15/31

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/324, 326, 327, 328, 329, 350, 387.9; 536/23.7; 514/12, 13, 14, 15, 16

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG, SEQUENCE DATA BASES, CAS REGISTRY FILE, search terms: sequence of SEQ ID NOS: 1-6 and 29 and chemotactic and monocytic

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>X</u> Y	Biochemical and Biophysical Research Communications, Volume 177, Number 2, issued 14 June 1991, Almeida et al., "Complementary DNA Sequence of Human Neutrophil Azurocidin, an Antibiotic with Extensive Homology to Serine Proteases", pages 688-695, see especially pages 690 and 693.	<u>1,3,6,8,10,12-15,33</u> 16-32
<u>X</u> Y	US, A, 5,087,569 (Gabay et al.) 11 February 1992, see entire document, especially Figure 14; claim 1; column 1; column 2, lines 39-48; column 6, lines 58-62; column 12, lines 16-30; and column 13, lines 24-43.	<u>1,3,6,8,10</u> 16,18,20, 22-33
<u>X</u> Y	US, A, 4,427,660 (Schiffman et al.) 24 January 1984, see entire document, especially the abstract and columns 8, 14, 17 and 18.	<u>16,19-25,27-29</u> 18
Y	US, A, 4,889,919 (Murray et al.) 26 December 1989, see column 13, lines 49-58.	18

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

13 May 1993

Date of mailing of the international search report

07 JUN 1993

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

KEITH C. FURMAN, PH.D.

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US93/02580

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Stedman, Thomas Lathrop, "Stedman's Medical Dictionary", published 1982 by Waverly Press, Inc. (Baltimore, MD), see p. 1051.	1-33

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/02580

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

530/324, 326, 327, 328, 329, 350, 387.9; 536/23.7; 514/12, 13, 14, 15, 16

**THIS PAGE BLANK (USPTO)**